MaxTay的个人主页 - 老虎社区

MaxTay

暂无个人介绍

IP属地：未知

11关注

1粉丝

0主题

0勋章

2021-06-27

Ok ok ok its hard to get a T

2021-06-27

Help me get a T

5 Buffett Stocks to Buy Hand Over Fist for the Second Half of 2021

2021-06-25

Say sth to get a 'T'

2021-06-25

I post to get a 'T'

抱歉，原内容已删除

2021-06-24

Like and comment, thanks guys

Vipshop Holdings: A Solid Valuation Play

2021-06-23

Comment everyday just for a T

抱歉，原内容已删除

2021-06-23

Post everyday just for a T

2021-06-22

Post sth

2021-06-22

Thanks for commenting

These 3 Dow Stocks Are Set to Soar in 2021's Second Half

2021-06-19

Come and like

GEO Stock: Shares of Recent Reddit Play GEO Group Surge on CEO Buy-In

2021-06-19

Another post

2021-06-18

Post, post

2021-06-18

Like for me

Dosing underway in BioNTech's Phase 2 trial of mrna-based BNT111 in advanced melanoma

2021-06-17

Quest

抱歉，原内容已删除

2021-06-17

Ok

抱歉，原内容已删除

2021-06-16

Ok

抱歉，原内容已删除

2021-06-16

Ok

抱歉，原内容已删除

2021-06-15

Tiger broker 1st post

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3570873824164040","uuid":"3570873824164040","gmtCreate":1607780463734,"gmtModify":1607780463734,"name":"MaxTay","pinyin":"maxtay","introduction":"","introductionEn":"","signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":11,"tweetSize":18,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"228c86a078844d74991fff2b7ab2428d-1","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资经理虎","description":"证券账户累计交易金额达到10万美元","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"60.90%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.04.27","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"35ec162348d5460f88c959321e554969-2","templateUuid":"35ec162348d5460f88c959321e554969","name":"宗师交易员","description":"证券或期货账户累计交易次数达到100次","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"80.34%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.18","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":124755158,"gmtCreate":1624796533174,"gmtModify":1631891440549,"author":{"id":"3570873824164040","authorId":"3570873824164040","name":"MaxTay","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570873824164040","authorIdStr":"3570873824164040"},"themes":[],"htmlText":"Ok ok ok its hard to get a T","listText":"Ok ok ok its hard to get a T","text":"Ok ok ok its hard to get a T","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/124755158","isVote":1,"tweetType":1,"viewCount":284,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":124752110,"gmtCreate":1624796439130,"gmtModify":1631891440557,"author":{"id":"3570873824164040","authorId":"3570873824164040","name":"MaxTay","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570873824164040","authorIdStr":"3570873824164040"},"themes":[],"htmlText":"Help me get a T","listText":"Help me get a T","text":"Help me get a T","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/124752110","repostId":"2146090006","repostType":4,"repost":{"id":"2146090006","kind":"highlight","pubTimestamp":1624755315,"share":"https://www.laohu8.com/m/news/2146090006?lang=&edition=full","pubTime":"2021-06-27 08:55","market":"us","language":"en","title":"5 Buffett Stocks to Buy Hand Over Fist for the Second Half of 2021","url":"https://stock-news.laohu8.com/highlight/detail?id=2146090006","media":"Motley Fool","summary":"These growth and value stocks are begging to be bought by investors.","content":"<p>When Warren Buffett buys or sells a stock, Wall Street and retail investors tend to pay very close attention. That's because the Oracle of Omaha's track record is virtually unsurpassed. Since taking the reins of <b>Berkshire Hathaway</b> (NYSE:BRK.A)(NYSE:BRK.B) in the mid-1960s, Buffett's company has averaged an annual return of 20%. This works out to an aggregate gain of greater than 2,800,000% for its Class A shares.</p>\n<p>Although Buffett isn't perfect, he and his investing team have a knack for identifying attractively valued businesses that have clear competitive advantages. As we prepare to move into the second half of 2021, the following five Buffett stocks stand out as those that should be bought hand over fist.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1077c8372814d2b8150e933b4c608005\" tg-width=\"700\" tg-height=\"466\"><span>Berkshire Hathaway CEO Warren Buffett. Image source: The Motley Fool.</span></p>\n<h2>Amazon</h2>\n<p>Even though Buffett's investing lieutenants, Todd Combs and Ted Weschler, are the architects behind Berkshire Hathaway's stake in <b>Amazon</b> (NASDAQ:AMZN), it's arguably the Buffett stock that should be bought most aggressively ahead of the second half of the year.</p>\n<p>As most folks probably know, Amazon is an e-commerce juggernaut. Based on an April report from eMarketer, the company effectively controls $0.40 of every $1 spent online in the United States. It's also pivoted its online retail popularity into signing up more than 200 million people to its Prime program worldwide. The fees Amazon collects from Prime help it to undercut its competition on price. And it certainly doesn't hurt that Prime members tend to spend many multiples more than non-Prime shoppers during the course of the year.</p>\n<p>But it's the company's cloud infrastructure service, Amazon Web Services (AWS), that has truly budded into a star. Since the operating margins associated with cloud infrastructure are considerably higher than what Amazon nets from retail and advertising, AWS' growth is leading to a surge in operating cash flow. If investors were to continue to pay the midpoint of Amazon's operating cash flow multiple over the past decade, it could hit $10,000 a share by 2025.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b18b49b2b35da2fc49e0a83b883d1c22\" tg-width=\"700\" tg-height=\"466\"><span>Image source: Getty Images.</span></p>\n<h2>Bristol Myers Squibb</h2>\n<p>Pharmaceutical stocks are money machines, and none looks to be more attractive on a valuation basis than <b>Bristol Myers Squibb</b> (NYSE:BMY).</p>\n<p>One reason to be excited about this drug developer is its organic growth potential. Eliquis, which was co-developed with <b>Pfizer</b>, has blossomed into the world's leading oral anticoagulant, with sales expected to surpass $10 billion in 2021. Meanwhile, dozens of additional clinical trials are underway for cancer immunotherapy Opdivo, which generated $7 billion in sales last year. This offers plenty of opportunity to expand Opdivo's label and pump up its pricing power.</p>\n<p>Another reason Bristol Myers Squibb is such an intriguing stock is its November 2019 acquisition of cancer and immunology company Celgene. Buying Celgene brought the blockbuster multiple-myeloma drug Revlimid into the fold. Revlimid has sustainably grown its annual sales by a double-digit percentage for more than a decade, with label expansion, longer duration of use, and pricing power all playing a role. This key treatment, which topped $12 billion in sales last year, is protected from a full onslaught of generic competition until early 2026. That means Bristol Myers will be rolling in the dough for another five years, at minimum.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1b152e369d7c967dcbc926192ee888c1\" tg-width=\"700\" tg-height=\"531\"><span>Image source: Getty Images.</span></p>\n<h2>Mastercard</h2>\n<p>Everyone seems to be looking for the smartest recovery play from the pandemic. Payment processor <b>Mastercard</b> (NYSE:MA) might well be the safest way to take advantage of a steady uptick in consumer and enterprise spending.</p>\n<p>Mastercard isn't a cheap stock by any means -- at 36 times Wall Street's forward-year earnings consensus -- but it benefits from a simple numbers game. While economic contractions and recessions are inevitable, these periods of turbulence tend to be short-lived. By comparison, economic expansions often last many years. Buying into Mastercard allows investors to take full advantage of these long periods of economic expansion and robust spending. Plus, it doesn't hurt that Mastercard has the second-highest share of credit-card network purchase volume in the U.S., the leading market for consumption.</p>\n<p>Investors can also sleep easy with the understanding that Mastercard strictly sticks to payment facilitation. Even though some of its peers also lend, and are therefore able to generate interest income and fees during bull markets, Mastercard has avoided becoming a lender. It's something you'll truly appreciate when a recession strikes. Whereas most financial stocks will be forced to set aside capital to cover credit or loan delinquencies, Mastercard won't have to. This is a big reason it bounces back from recessions quicker than most financial stocks.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/e4e1a1fe028efa4c966b66ef2cd466f5\" tg-width=\"700\" tg-height=\"466\"><span>Image source: Getty Images.</span></p>\n<h2>Teva Pharmaceutical Industries</h2>\n<p>If you have an appetite for turnaround plays, brand-name and generic-drug developer <b>Teva Pharmaceutical Industries</b> (NYSE:TEVA) is the stock to buy hand over fist for the second half of 2021. Like Amazon, it's a stock that was added to Berkshire Hathaway's portfolio by either Combs or Weschler and not Buffett.</p>\n<p>While there's no denying that Teva has its fair share of hurdles to overcome, the company's turnaround-focused CEO, Kare Schultz, has been a blessing. Since taking the helm less than four years ago, Schultz has helped shave off more than $10 billion in net debt, and he's overseen the reduction of roughly $3 billion in annual operating expenses. There's more work to do to improve Teva's balance sheet, but the company is very clearly on much firmer ground than it was back in 2016-2017.</p>\n<p>Schultz also has the potential to play peacemaker for a number of outstanding lawsuits targeting Teva's role in the opioid crisis. If this litigation can be resolved with minimal cash outlay, Teva's valuation could soar. At just 4 times the company's projected earnings in 2021, Teva is about as cheap as a healthcare stock can get.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/44a30c4dfd6886a29e22d3c6558c3e56\" tg-width=\"700\" tg-height=\"466\"><span>Image source: Getty Images.</span></p>\n<h2>Bank of America</h2>\n<p>Lastly, bank stock <b>Bank of America</b> (NYSE:BAC) has the look of a company that can be confidently bought hand over fist for the second half of 2021.</p>\n<p>For much of the past decade, the Federal Reserve has kept interest rates at or near historic lows. That's meant less in the way of interest income for banks. But the latest update from the nation's central bank suggests that interest rates could begin creeping up in 2023, a year earlier than previously forecast. Bank of America is the most interest-sensitive money-center bank. According to its first-quarter investor presentation, BofA would generate $8.3 billion in net interest income on a 100-basis-point shift in the interest rate yield curve. Translation: Bank of America's profits should rocket higher beginning in 2023-2024.</p>\n<p>At the same time, BofA has done an outstanding job of controlling its costs and improving its operating efficiency. Investments in digitization have resulted in higher mobile app and digital banking use, which is allowing the company to consolidate some of its branches. Even with its shares at a 13-year high, Bank of America has plenty left in the tank.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Buffett Stocks to Buy Hand Over Fist for the Second Half of 2021</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Buffett Stocks to Buy Hand Over Fist for the Second Half of 2021\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-27 08:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/26/buffett-stocks-buy-hand-over-fist-second-half-2021/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>When Warren Buffett buys or sells a stock, Wall Street and retail investors tend to pay very close attention. That's because the Oracle of Omaha's track record is virtually unsurpassed. Since taking ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/26/buffett-stocks-buy-hand-over-fist-second-half-2021/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BAC":"美国银行","MA":"万事达","BRK.A":"伯克希尔","TEVA":"梯瓦制药","AMZN":"亚马逊","BMY":"施贵宝","BRK.B":"伯克希尔B"},"source_url":"https://www.fool.com/investing/2021/06/26/buffett-stocks-buy-hand-over-fist-second-half-2021/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2146090006","content_text":"When Warren Buffett buys or sells a stock, Wall Street and retail investors tend to pay very close attention. That's because the Oracle of Omaha's track record is virtually unsurpassed. Since taking the reins of Berkshire Hathaway (NYSE:BRK.A)(NYSE:BRK.B) in the mid-1960s, Buffett's company has averaged an annual return of 20%. This works out to an aggregate gain of greater than 2,800,000% for its Class A shares.\nAlthough Buffett isn't perfect, he and his investing team have a knack for identifying attractively valued businesses that have clear competitive advantages. As we prepare to move into the second half of 2021, the following five Buffett stocks stand out as those that should be bought hand over fist.\nBerkshire Hathaway CEO Warren Buffett. Image source: The Motley Fool.\nAmazon\nEven though Buffett's investing lieutenants, Todd Combs and Ted Weschler, are the architects behind Berkshire Hathaway's stake in Amazon (NASDAQ:AMZN), it's arguably the Buffett stock that should be bought most aggressively ahead of the second half of the year.\nAs most folks probably know, Amazon is an e-commerce juggernaut. Based on an April report from eMarketer, the company effectively controls $0.40 of every $1 spent online in the United States. It's also pivoted its online retail popularity into signing up more than 200 million people to its Prime program worldwide. The fees Amazon collects from Prime help it to undercut its competition on price. And it certainly doesn't hurt that Prime members tend to spend many multiples more than non-Prime shoppers during the course of the year.\nBut it's the company's cloud infrastructure service, Amazon Web Services (AWS), that has truly budded into a star. Since the operating margins associated with cloud infrastructure are considerably higher than what Amazon nets from retail and advertising, AWS' growth is leading to a surge in operating cash flow. If investors were to continue to pay the midpoint of Amazon's operating cash flow multiple over the past decade, it could hit $10,000 a share by 2025.\nImage source: Getty Images.\nBristol Myers Squibb\nPharmaceutical stocks are money machines, and none looks to be more attractive on a valuation basis than Bristol Myers Squibb (NYSE:BMY).\nOne reason to be excited about this drug developer is its organic growth potential. Eliquis, which was co-developed with Pfizer, has blossomed into the world's leading oral anticoagulant, with sales expected to surpass $10 billion in 2021. Meanwhile, dozens of additional clinical trials are underway for cancer immunotherapy Opdivo, which generated $7 billion in sales last year. This offers plenty of opportunity to expand Opdivo's label and pump up its pricing power.\nAnother reason Bristol Myers Squibb is such an intriguing stock is its November 2019 acquisition of cancer and immunology company Celgene. Buying Celgene brought the blockbuster multiple-myeloma drug Revlimid into the fold. Revlimid has sustainably grown its annual sales by a double-digit percentage for more than a decade, with label expansion, longer duration of use, and pricing power all playing a role. This key treatment, which topped $12 billion in sales last year, is protected from a full onslaught of generic competition until early 2026. That means Bristol Myers will be rolling in the dough for another five years, at minimum.\nImage source: Getty Images.\nMastercard\nEveryone seems to be looking for the smartest recovery play from the pandemic. Payment processor Mastercard (NYSE:MA) might well be the safest way to take advantage of a steady uptick in consumer and enterprise spending.\nMastercard isn't a cheap stock by any means -- at 36 times Wall Street's forward-year earnings consensus -- but it benefits from a simple numbers game. While economic contractions and recessions are inevitable, these periods of turbulence tend to be short-lived. By comparison, economic expansions often last many years. Buying into Mastercard allows investors to take full advantage of these long periods of economic expansion and robust spending. Plus, it doesn't hurt that Mastercard has the second-highest share of credit-card network purchase volume in the U.S., the leading market for consumption.\nInvestors can also sleep easy with the understanding that Mastercard strictly sticks to payment facilitation. Even though some of its peers also lend, and are therefore able to generate interest income and fees during bull markets, Mastercard has avoided becoming a lender. It's something you'll truly appreciate when a recession strikes. Whereas most financial stocks will be forced to set aside capital to cover credit or loan delinquencies, Mastercard won't have to. This is a big reason it bounces back from recessions quicker than most financial stocks.\nImage source: Getty Images.\nTeva Pharmaceutical Industries\nIf you have an appetite for turnaround plays, brand-name and generic-drug developer Teva Pharmaceutical Industries (NYSE:TEVA) is the stock to buy hand over fist for the second half of 2021. Like Amazon, it's a stock that was added to Berkshire Hathaway's portfolio by either Combs or Weschler and not Buffett.\nWhile there's no denying that Teva has its fair share of hurdles to overcome, the company's turnaround-focused CEO, Kare Schultz, has been a blessing. Since taking the helm less than four years ago, Schultz has helped shave off more than $10 billion in net debt, and he's overseen the reduction of roughly $3 billion in annual operating expenses. There's more work to do to improve Teva's balance sheet, but the company is very clearly on much firmer ground than it was back in 2016-2017.\nSchultz also has the potential to play peacemaker for a number of outstanding lawsuits targeting Teva's role in the opioid crisis. If this litigation can be resolved with minimal cash outlay, Teva's valuation could soar. At just 4 times the company's projected earnings in 2021, Teva is about as cheap as a healthcare stock can get.\nImage source: Getty Images.\nBank of America\nLastly, bank stock Bank of America (NYSE:BAC) has the look of a company that can be confidently bought hand over fist for the second half of 2021.\nFor much of the past decade, the Federal Reserve has kept interest rates at or near historic lows. That's meant less in the way of interest income for banks. But the latest update from the nation's central bank suggests that interest rates could begin creeping up in 2023, a year earlier than previously forecast. Bank of America is the most interest-sensitive money-center bank. According to its first-quarter investor presentation, BofA would generate $8.3 billion in net interest income on a 100-basis-point shift in the interest rate yield curve. Translation: Bank of America's profits should rocket higher beginning in 2023-2024.\nAt the same time, BofA has done an outstanding job of controlling its costs and improving its operating efficiency. Investments in digitization have resulted in higher mobile app and digital banking use, which is allowing the company to consolidate some of its branches. Even with its shares at a 13-year high, Bank of America has plenty left in the tank.","news_type":1},"isVote":1,"tweetType":1,"viewCount":249,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":122694491,"gmtCreate":1624615270313,"gmtModify":1631891440570,"author":{"id":"3570873824164040","authorId":"3570873824164040","name":"MaxTay","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570873824164040","authorIdStr":"3570873824164040"},"themes":[],"htmlText":"Say sth to get a 'T'","listText":"Say sth to get a 'T'","text":"Say sth to get a 'T'","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/122694491","isVote":1,"tweetType":1,"viewCount":192,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":122695762,"gmtCreate":1624615189056,"gmtModify":1631891440582,"author":{"id":"3570873824164040","authorId":"3570873824164040","name":"MaxTay","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570873824164040","authorIdStr":"3570873824164040"},"themes":[],"htmlText":"I post to get a 'T'","listText":"I post to get a 'T'","text":"I post to get a 'T'","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/122695762","repostId":"2146023165","repostType":4,"isVote":1,"tweetType":1,"viewCount":287,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":128587199,"gmtCreate":1624523938511,"gmtModify":1631891440595,"author":{"id":"3570873824164040","authorId":"3570873824164040","name":"MaxTay","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570873824164040","authorIdStr":"3570873824164040"},"themes":[],"htmlText":"Like and comment, thanks guys&nbsp;","listText":"Like and comment, thanks guys&nbsp;","text":"Like and comment, thanks guys","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/128587199","repostId":"1186718506","repostType":4,"repost":{"id":"1186718506","kind":"news","pubTimestamp":1624523657,"share":"https://www.laohu8.com/m/news/1186718506?lang=&edition=full","pubTime":"2021-06-24 16:34","market":"us","language":"en","title":"Vipshop Holdings: A Solid Valuation Play","url":"https://stock-news.laohu8.com/highlight/detail?id=1186718506","media":"seekingalpha","summary":"Summary\n\nSolid valuation play with strong fundamentals.\nOwner-operated business with a meaningful ow","content":"<p><b>Summary</b></p>\n<ul>\n <li>Solid valuation play with strong fundamentals.</li>\n <li>Owner-operated business with a meaningful ownership stakes in the company.</li>\n <li>Cooperation with JD.com and Tencent provides opportunity for future growth.</li>\n</ul>\n<p><b>Investment Thesis</b></p>\n<p><b>Vipshop Holdings Ltd. (VIPS)</b>&nbsp;is a Chinese online retailer with a focus on sale of discounted branded products in limited quantities for a short period of time, also known in the retail industry as a flash sales business model. The stock price went through a roller-coaster ride when in the first two months of this year generated a return of 60% just to give it all back and ended this month with a YTD loss of nearly 40%. In the past few months, the stock was affected by the investigation of Chinese regulators for unfair retail practices, which continued with a selloff due to the block trade tied to the collapse of hedge fund Archegos. If this was not enough, then the current discussion about the regulation of Chinese e-commerce companies is putting additional pressure on the stock performance. In the following paragraphs, I want to show that behind the negative sentiment hides a company with growing revenues and solid fundaments which are unfairly discounted at the current price.</p>\n<p><img src=\"https://static.tigerbbs.com/34c55d9a6241719942a6f034ead1e063\" tg-width=\"640\" tg-height=\"379\"></p>\n<p><i>Source: Bloomberg</i></p>\n<p><b>Company overview</b></p>\n<p>Before jumping straight into operational characteristics, it is always good to look at the ownership structure of the company. The company has two classes of shares. Class B shares are 100% owned by its CEO and founder Eric Ya Shen, who owns 12% of total shares. Another co-founder Arthur Xiaobo Hong owns 6.9% of total shares. These two founders together own 19% of the company stock. It is always good to see that both founders have \"skin in the game\" and their ownership stakes constitute majority of their net worth. Other major investors are Tencent(OTCPK:TCEHY)and JD.com(NASDAQ:JD)which altogether hold a 17% stake in the company, which I consider to be a proof that Vipshop is a solid company, not just some e-commerce scam.</p>\n<p>This alliance with Tencent and JD.com serves to protect Vipshop's business model from major competitors, especially Alibaba(NYSE:BABA)and Pinduoduo(NASDAQ:PDD), due to lowering acquisition costs of new customers and at the same time re-directing these customers to the Vipshop platform. At the end of Q1 2021, Vipshop had 46 million customers, GMV of USD 7.1 billion and cooperated with approximately 21,000 brands. That is quite impressive compared to what this business is currently worth.</p>\n<p><b>Valuation</b></p>\n<p>With Chinese tech companies, it is generally true that they are either loved or hated. You can buy them either with a huge premium or a big discount compared to their intrinsic value. In case of Vipshop, I would argue that is unfairly discounted, which makes it an attractive buying opportunity at current prices.</p>\n<p>There are several ways how an investor can look at the valuation of the company. In this analysis, I look at the valuation from several perspectives. More specifically, I look at the multiples of the company versus its historical multiples, the multiples of the competition and finally multiples of the market itself. I understand that some might argue that a proper valuation of the company requires a DCF analysis, but in this case, I think that relative valuation is sufficient to prove the point.</p>\n<p><img src=\"https://static.tigerbbs.com/b9c6aa80618d53dfe075349bcfb66f14\" tg-width=\"613\" tg-height=\"103\" referrerpolicy=\"no-referrer\"></p>\n<p>At current levels, VIPS is trading approximately 30% below is 2-year average. Comparing VIPS to index SP500, the difference is even more striking. The same pattern is visible if you compare VIPS to its closest competitors: Alibaba, Pinduoduo and JD.com</p>\n<p><img src=\"https://static.tigerbbs.com/8eab4b8077e4df714728dfc2ee7787c7\" tg-width=\"512\" tg-height=\"104\"></p>\n<p>From a fundamental perspective, VIPS looks like a solid investment. It is net cash positive (USD 2.3 billion in 1Q21) and generates over USD 1.1 billion in FCFF with FCFF yield over 11%. Based on the management comments, it expects to grow revenues from 20% to 25% in Q2 and c. 30% in FY21. Additionally, it expects to repurchase USD 500 mil. worth of shares in next two years.</p>\n<p><b>Summary</b></p>\n<p>After a string of negative events in the past 4 months, VIPS underwent a path from being a darling of the market to become a total underdog. Even though, the stock collapsed more than 60% from the top, the underlying business is still intact and fundamentally strong. The business itself is net cash positive, generating positive FCFF. All in all, VIPS is a valuation play which offers 30% to 40% discount at the current price. Can VIPS trade even lower? Yes, it definitely can. However, patient investors who are willing to slowly build their position and who can wait for the valuation gap to close can be rewarded with above-average return in the not-so-distant future.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vipshop Holdings: A Solid Valuation Play</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVipshop Holdings: A Solid Valuation Play\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-24 16:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4436316-vipshop-holdings-solid-valuation-play><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Summary\n\nSolid valuation play with strong fundamentals.\nOwner-operated business with a meaningful ownership stakes in the company.\nCooperation with JD.com and Tencent provides opportunity for future ...</p>\n\n<a href=\"https://seekingalpha.com/article/4436316-vipshop-holdings-solid-valuation-play\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VIPS":"唯品会"},"source_url":"https://seekingalpha.com/article/4436316-vipshop-holdings-solid-valuation-play","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1186718506","content_text":"Summary\n\nSolid valuation play with strong fundamentals.\nOwner-operated business with a meaningful ownership stakes in the company.\nCooperation with JD.com and Tencent provides opportunity for future growth.\n\nInvestment Thesis\nVipshop Holdings Ltd. (VIPS) is a Chinese online retailer with a focus on sale of discounted branded products in limited quantities for a short period of time, also known in the retail industry as a flash sales business model. The stock price went through a roller-coaster ride when in the first two months of this year generated a return of 60% just to give it all back and ended this month with a YTD loss of nearly 40%. In the past few months, the stock was affected by the investigation of Chinese regulators for unfair retail practices, which continued with a selloff due to the block trade tied to the collapse of hedge fund Archegos. If this was not enough, then the current discussion about the regulation of Chinese e-commerce companies is putting additional pressure on the stock performance. In the following paragraphs, I want to show that behind the negative sentiment hides a company with growing revenues and solid fundaments which are unfairly discounted at the current price.\n\nSource: Bloomberg\nCompany overview\nBefore jumping straight into operational characteristics, it is always good to look at the ownership structure of the company. The company has two classes of shares. Class B shares are 100% owned by its CEO and founder Eric Ya Shen, who owns 12% of total shares. Another co-founder Arthur Xiaobo Hong owns 6.9% of total shares. These two founders together own 19% of the company stock. It is always good to see that both founders have \"skin in the game\" and their ownership stakes constitute majority of their net worth. Other major investors are Tencent(OTCPK:TCEHY)and JD.com(NASDAQ:JD)which altogether hold a 17% stake in the company, which I consider to be a proof that Vipshop is a solid company, not just some e-commerce scam.\nThis alliance with Tencent and JD.com serves to protect Vipshop's business model from major competitors, especially Alibaba(NYSE:BABA)and Pinduoduo(NASDAQ:PDD), due to lowering acquisition costs of new customers and at the same time re-directing these customers to the Vipshop platform. At the end of Q1 2021, Vipshop had 46 million customers, GMV of USD 7.1 billion and cooperated with approximately 21,000 brands. That is quite impressive compared to what this business is currently worth.\nValuation\nWith Chinese tech companies, it is generally true that they are either loved or hated. You can buy them either with a huge premium or a big discount compared to their intrinsic value. In case of Vipshop, I would argue that is unfairly discounted, which makes it an attractive buying opportunity at current prices.\nThere are several ways how an investor can look at the valuation of the company. In this analysis, I look at the valuation from several perspectives. More specifically, I look at the multiples of the company versus its historical multiples, the multiples of the competition and finally multiples of the market itself. I understand that some might argue that a proper valuation of the company requires a DCF analysis, but in this case, I think that relative valuation is sufficient to prove the point.\n\nAt current levels, VIPS is trading approximately 30% below is 2-year average. Comparing VIPS to index SP500, the difference is even more striking. The same pattern is visible if you compare VIPS to its closest competitors: Alibaba, Pinduoduo and JD.com\n\nFrom a fundamental perspective, VIPS looks like a solid investment. It is net cash positive (USD 2.3 billion in 1Q21) and generates over USD 1.1 billion in FCFF with FCFF yield over 11%. Based on the management comments, it expects to grow revenues from 20% to 25% in Q2 and c. 30% in FY21. Additionally, it expects to repurchase USD 500 mil. worth of shares in next two years.\nSummary\nAfter a string of negative events in the past 4 months, VIPS underwent a path from being a darling of the market to become a total underdog. Even though, the stock collapsed more than 60% from the top, the underlying business is still intact and fundamentally strong. The business itself is net cash positive, generating positive FCFF. All in all, VIPS is a valuation play which offers 30% to 40% discount at the current price. Can VIPS trade even lower? Yes, it definitely can. However, patient investors who are willing to slowly build their position and who can wait for the valuation gap to close can be rewarded with above-average return in the not-so-distant future.","news_type":1},"isVote":1,"tweetType":1,"viewCount":156,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":121027965,"gmtCreate":1624445769157,"gmtModify":1631891440608,"author":{"id":"3570873824164040","authorId":"3570873824164040","name":"MaxTay","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570873824164040","authorIdStr":"3570873824164040"},"themes":[],"htmlText":"Comment everyday just for a T","listText":"Comment everyday just for a T","text":"Comment everyday just for a T","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/121027965","repostId":"1127447179","repostType":4,"isVote":1,"tweetType":1,"viewCount":162,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":121024326,"gmtCreate":1624445739365,"gmtModify":1631884647014,"author":{"id":"3570873824164040","authorId":"3570873824164040","name":"MaxTay","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570873824164040","authorIdStr":"3570873824164040"},"themes":[],"htmlText":"Post everyday just for a T","listText":"Post everyday just for a T","text":"Post everyday just for a T","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/121024326","isVote":1,"tweetType":1,"viewCount":144,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":129105915,"gmtCreate":1624363054537,"gmtModify":1631884647043,"author":{"id":"3570873824164040","authorId":"3570873824164040","name":"MaxTay","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570873824164040","authorIdStr":"3570873824164040"},"themes":[],"htmlText":"Post sth","listText":"Post sth","text":"Post sth","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/129105915","isVote":1,"tweetType":1,"viewCount":514,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":129377952,"gmtCreate":1624362593076,"gmtModify":1631891440621,"author":{"id":"3570873824164040","authorId":"3570873824164040","name":"MaxTay","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570873824164040","authorIdStr":"3570873824164040"},"themes":[],"htmlText":"Thanks for commenting","listText":"Thanks for commenting","text":"Thanks for commenting","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/129377952","repostId":"2145056554","repostType":4,"repost":{"id":"2145056554","kind":"highlight","pubTimestamp":1624356900,"share":"https://www.laohu8.com/m/news/2145056554?lang=&edition=full","pubTime":"2021-06-22 18:15","market":"us","language":"en","title":"These 3 Dow Stocks Are Set to Soar in 2021's Second Half","url":"https://stock-news.laohu8.com/highlight/detail?id=2145056554","media":"Motley Fool","summary":"Here are the companies investors are most excited about -- and why.","content":"<p>The <b>Dow Jones Industrial Average </b>(DJINDICES:^DJI) has had a solid year so far in 2021. Gains of 9% might not seem like all that much compared to the double-digit percentage gains we've seen in past years. But given everything that's happening in the economy, it's not surprising to see investors rein in their expectations somewhat on some of the top-performing stocks in the market.</p>\n<p>Yet even with the gains the overall market has seen, there are still some Dow stocks that haven't climbed as far as they might. In particular, analysts looking at three stocks among the Dow Jones Industrials see the potential for substantial gains in the second half of 2021 and beyond. Below, we'll look at these three companies to see what it'll take for them to produce the big returns that investors want right now.</p>\n<h3>UnitedHealth: 34% upside</h3>\n<p><b>UnitedHealth Group </b>(NYSE:UNH) has already put in a reasonable performance in the Dow so far this year. The health insurance giant's stock is up about 11% year to date, outpacing the broader average very slightly.</p>\n<p>Yet investors see a lot more upside for the healthcare giant. The top price target among Wall Street analysts for UnitedHealth is $522 per share, which implies roughly a 34% gain from current levels.</p>\n<p>UnitedHealth has done an excellent job of navigating the ever-changing landscape of the healthcare and health insurance industries. As the largest health insurance company in the world, UnitedHealth offers coverage not just for private businesses but also for those eligible for government programs like Medicare and Medicaid.</p>\n<p>Indeed, UnitedHealth's handling of plans under the Affordable Care Act has been masterful, with the company having participated in the program better known as Obamacare while not overcommitting to it. With the Supreme Court having recently upheld the validity of the Affordable Care Act, UnitedHealth finds itself in a strong position to keep benefiting from its mix of business.</p>\n<p><img src=\"https://static.tigerbbs.com/ffe66b7aafd67e07dd42007f2b60d638\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<p>Yet many overlook the value of UnitedHealth's Optum health services unit. By aiming to help providers encourage health and wellness, Optum generates higher-margin revenue while often producing better outcomes for patients and members. With both growth drivers pushing the company forward, UnitedHealth looks well poised to keep climbing.</p>\n<h3>Goldman Sachs: 36% upside</h3>\n<p>Wall Street has enjoyed the bull market in stocks, and that's been a blessing for investment bank <b>Goldman Sachs </b>(NYSE:GS). The perennial financial giant has seen its stock rise 34% so far in 2021 after less impressive performance during 2020.</p>\n<p>On <a href=\"https://laohu8.com/S/AONE\">one</a> hand, Goldman has reflected the broader performance of financial stocks across the market. Interest rates have generally been on the rise, and that's bolstered the prospects for more net-interest income from retail banking operations. Goldman lags behind its big-bank peers on the consumer banking front, but its relatively new Marcus unit has done a good job of attracting capital thus far.</p>\n<p>On the other hand, Goldman continues to rely on its investment banking operations, and strong activity levels among initial public offerings and mergers and acquisitions (M&amp;A) have fed the company's coffers nicely. Financing remains relatively easy to get, and that could spur more M&amp;A activity that in turn could keep growing revenue for Goldman's investment banking division. Add to that possible tailwinds from macroeconomic factors, and it is in a solid position to climb as high as the $484 per share that represents the top price target among those following the financial stock.</p>\n<h3>Apple: 42% upside</h3>\n<p>Lastly, <b>Apple </b>(NASDAQ:AAPL) rounds out this list. Recently fetching $130 per share, some see the iPhone maker's stock climbing to $185. That'd be a 42% jump to help Apple recover from its 2% loss so far in 2021.</p>\n<p>Apple's gains have continued to impress. Revenue jumped 54% in its most recent quarter, with sales of the iPhone 12 and various other products and accessories continuing to drive sales for the company. Returning capital to shareholders via dividends and stock buybacks has had a substantial impact on financial performance, especially with the number of outstanding shares having plunged by roughly 35% in just the past decade.</p>\n<p>Many fear that Apple hasn't generated the innovative product lines that drove its success in the mid-2000s. However, at least for now, consumers seem content with iterations on existing product lines, and as long as that remains a successful strategy, further gains for the stock seem realistic.</p>\n<h3>Further to run?</h3>\n<p>Even with solid gains for the Dow in 2021, the long-term trajectory for stocks remains upward. That's a big part of why Apple, Goldman Sachs, and UnitedHealth Group look as promising as they do. Smart investors should at least keep an eye on these three stocks to see if they can live up to their full potential.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>These 3 Dow Stocks Are Set to Soar in 2021's Second Half</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThese 3 Dow Stocks Are Set to Soar in 2021's Second Half\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-22 18:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/22/these-3-dow-stocks-set-to-soar-2021s-second-half/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The Dow Jones Industrial Average (DJINDICES:^DJI) has had a solid year so far in 2021. Gains of 9% might not seem like all that much compared to the double-digit percentage gains we've seen in past ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/22/these-3-dow-stocks-set-to-soar-2021s-second-half/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"UNH":"联合健康","AAPL":"苹果","03086":"华夏纳指","GS":"高盛","09086":"华夏纳指-U"},"source_url":"https://www.fool.com/investing/2021/06/22/these-3-dow-stocks-set-to-soar-2021s-second-half/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2145056554","content_text":"The Dow Jones Industrial Average (DJINDICES:^DJI) has had a solid year so far in 2021. Gains of 9% might not seem like all that much compared to the double-digit percentage gains we've seen in past years. But given everything that's happening in the economy, it's not surprising to see investors rein in their expectations somewhat on some of the top-performing stocks in the market.\nYet even with the gains the overall market has seen, there are still some Dow stocks that haven't climbed as far as they might. In particular, analysts looking at three stocks among the Dow Jones Industrials see the potential for substantial gains in the second half of 2021 and beyond. Below, we'll look at these three companies to see what it'll take for them to produce the big returns that investors want right now.\nUnitedHealth: 34% upside\nUnitedHealth Group (NYSE:UNH) has already put in a reasonable performance in the Dow so far this year. The health insurance giant's stock is up about 11% year to date, outpacing the broader average very slightly.\nYet investors see a lot more upside for the healthcare giant. The top price target among Wall Street analysts for UnitedHealth is $522 per share, which implies roughly a 34% gain from current levels.\nUnitedHealth has done an excellent job of navigating the ever-changing landscape of the healthcare and health insurance industries. As the largest health insurance company in the world, UnitedHealth offers coverage not just for private businesses but also for those eligible for government programs like Medicare and Medicaid.\nIndeed, UnitedHealth's handling of plans under the Affordable Care Act has been masterful, with the company having participated in the program better known as Obamacare while not overcommitting to it. With the Supreme Court having recently upheld the validity of the Affordable Care Act, UnitedHealth finds itself in a strong position to keep benefiting from its mix of business.\n\nImage source: Getty Images.\nYet many overlook the value of UnitedHealth's Optum health services unit. By aiming to help providers encourage health and wellness, Optum generates higher-margin revenue while often producing better outcomes for patients and members. With both growth drivers pushing the company forward, UnitedHealth looks well poised to keep climbing.\nGoldman Sachs: 36% upside\nWall Street has enjoyed the bull market in stocks, and that's been a blessing for investment bank Goldman Sachs (NYSE:GS). The perennial financial giant has seen its stock rise 34% so far in 2021 after less impressive performance during 2020.\nOn one hand, Goldman has reflected the broader performance of financial stocks across the market. Interest rates have generally been on the rise, and that's bolstered the prospects for more net-interest income from retail banking operations. Goldman lags behind its big-bank peers on the consumer banking front, but its relatively new Marcus unit has done a good job of attracting capital thus far.\nOn the other hand, Goldman continues to rely on its investment banking operations, and strong activity levels among initial public offerings and mergers and acquisitions (M&A) have fed the company's coffers nicely. Financing remains relatively easy to get, and that could spur more M&A activity that in turn could keep growing revenue for Goldman's investment banking division. Add to that possible tailwinds from macroeconomic factors, and it is in a solid position to climb as high as the $484 per share that represents the top price target among those following the financial stock.\nApple: 42% upside\nLastly, Apple (NASDAQ:AAPL) rounds out this list. Recently fetching $130 per share, some see the iPhone maker's stock climbing to $185. That'd be a 42% jump to help Apple recover from its 2% loss so far in 2021.\nApple's gains have continued to impress. Revenue jumped 54% in its most recent quarter, with sales of the iPhone 12 and various other products and accessories continuing to drive sales for the company. Returning capital to shareholders via dividends and stock buybacks has had a substantial impact on financial performance, especially with the number of outstanding shares having plunged by roughly 35% in just the past decade.\nMany fear that Apple hasn't generated the innovative product lines that drove its success in the mid-2000s. However, at least for now, consumers seem content with iterations on existing product lines, and as long as that remains a successful strategy, further gains for the stock seem realistic.\nFurther to run?\nEven with solid gains for the Dow in 2021, the long-term trajectory for stocks remains upward. That's a big part of why Apple, Goldman Sachs, and UnitedHealth Group look as promising as they do. Smart investors should at least keep an eye on these three stocks to see if they can live up to their full potential.","news_type":1},"isVote":1,"tweetType":1,"viewCount":173,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":165064669,"gmtCreate":1624082010451,"gmtModify":1631891440632,"author":{"id":"3570873824164040","authorId":"3570873824164040","name":"MaxTay","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570873824164040","authorIdStr":"3570873824164040"},"themes":[],"htmlText":"Come and like","listText":"Come and like","text":"Come and like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/165064669","repostId":"1141597711","repostType":4,"repost":{"id":"1141597711","kind":"news","pubTimestamp":1624029257,"share":"https://www.laohu8.com/m/news/1141597711?lang=&edition=full","pubTime":"2021-06-18 23:14","market":"us","language":"en","title":"GEO Stock: Shares of Recent Reddit Play GEO Group Surge on CEO Buy-In","url":"https://stock-news.laohu8.com/highlight/detail?id=1141597711","media":"investorplace","summary":"GEO Group(NYSE:GEO) is heading higher on Friday following news that the company’s CEO acquired share","content":"<p><b>GEO Group</b>(NYSE:<b><u>GEO</u></b>) is heading higher on Friday following news that the company’s CEO acquired shares of the stock.</p>\n<p>According to a recent filing with the U.S. Securities and Exchange Commission (SEC), chairman and CEO George Zoley picked up an additional166,644 shares of GEO stock. The shares were purchase for prices ranging from $6.685 to $6.80 for an average paid price of $6.75 per share.</p>\n<p>News of the company’s CEO picking shares of GEO stock will likely excite investors betting on the company to rise higher. See, GEO has beentargeted by Redditas one of its new favorite stocks to invest in.</p>\n<p>With Reddit investing in GEO, that means shares of the company’s stock are experiencing a short-squeeze. This has investors buying and holding shares to force out hedge funds. The CEO buying more shares will likely be seen as a positive by Reddit traders.</p>\n<p>GEO Group is a company that offers rehabilitation services to prisons around the world. That includes offerings for bringing criminals back into society once their time has been served. It’s been in business since 1984 but didn’t change to its current name until 2003. You can learn more about the companyat this link.</p>\n<p>GEO stock was up 7.9% as of Friday morning.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GEO Stock: Shares of Recent Reddit Play GEO Group Surge on CEO Buy-In</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGEO Stock: Shares of Recent Reddit Play GEO Group Surge on CEO Buy-In\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-18 23:14 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/06/geo-stock-shares-of-recent-reddit-play-geo-group-surge-on-ceo-buy-in/><strong>investorplace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>GEO Group(NYSE:GEO) is heading higher on Friday following news that the company’s CEO acquired shares of the stock.\nAccording to a recent filing with the U.S. Securities and Exchange Commission (SEC),...</p>\n\n<a href=\"https://investorplace.com/2021/06/geo-stock-shares-of-recent-reddit-play-geo-group-surge-on-ceo-buy-in/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GEO":"GEO惩教集团"},"source_url":"https://investorplace.com/2021/06/geo-stock-shares-of-recent-reddit-play-geo-group-surge-on-ceo-buy-in/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1141597711","content_text":"GEO Group(NYSE:GEO) is heading higher on Friday following news that the company’s CEO acquired shares of the stock.\nAccording to a recent filing with the U.S. Securities and Exchange Commission (SEC), chairman and CEO George Zoley picked up an additional166,644 shares of GEO stock. The shares were purchase for prices ranging from $6.685 to $6.80 for an average paid price of $6.75 per share.\nNews of the company’s CEO picking shares of GEO stock will likely excite investors betting on the company to rise higher. See, GEO has beentargeted by Redditas one of its new favorite stocks to invest in.\nWith Reddit investing in GEO, that means shares of the company’s stock are experiencing a short-squeeze. This has investors buying and holding shares to force out hedge funds. The CEO buying more shares will likely be seen as a positive by Reddit traders.\nGEO Group is a company that offers rehabilitation services to prisons around the world. That includes offerings for bringing criminals back into society once their time has been served. It’s been in business since 1984 but didn’t change to its current name until 2003. You can learn more about the companyat this link.\nGEO stock was up 7.9% as of Friday morning.","news_type":1},"isVote":1,"tweetType":1,"viewCount":368,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":165065767,"gmtCreate":1624081977559,"gmtModify":1631891440642,"author":{"id":"3570873824164040","authorId":"3570873824164040","name":"MaxTay","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570873824164040","authorIdStr":"3570873824164040"},"themes":[],"htmlText":"Another post","listText":"Another post","text":"Another post","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/165065767","isVote":1,"tweetType":1,"viewCount":153,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":166415932,"gmtCreate":1624022395226,"gmtModify":1631891440654,"author":{"id":"3570873824164040","authorId":"3570873824164040","name":"MaxTay","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570873824164040","authorIdStr":"3570873824164040"},"themes":[],"htmlText":"Post, post","listText":"Post, post","text":"Post, post","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/166415932","isVote":1,"tweetType":1,"viewCount":101,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":166508320,"gmtCreate":1624015329960,"gmtModify":1631892621110,"author":{"id":"3570873824164040","authorId":"3570873824164040","name":"MaxTay","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570873824164040","authorIdStr":"3570873824164040"},"themes":[],"htmlText":"Like for me","listText":"Like for me","text":"Like for me","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/166508320","repostId":"1166489816","repostType":4,"repost":{"id":"1166489816","kind":"news","pubTimestamp":1624009298,"share":"https://www.laohu8.com/m/news/1166489816?lang=&edition=full","pubTime":"2021-06-18 17:41","market":"us","language":"en","title":"Dosing underway in BioNTech's Phase 2 trial of mrna-based BNT111 in advanced melanoma","url":"https://stock-news.laohu8.com/highlight/detail?id=1166489816","media":"seekingalpha","summary":"BioNTech(NASDAQ:BNTX)announcesthat the first patient has been treated in its Phase 2 cancer vaccine ","content":"<ul>\n <li>BioNTech(NASDAQ:BNTX)announcesthat the first patient has been treated in its Phase&nbsp;2 cancer vaccine trial, evaluating the Company’s BNT111in combination with Libtayo (cemiplimab), being co-developed by Regeneron(NASDAQ:REGN)and Sanofi(NASDAQ:SNY)in patients with anti-PD1-refractory/relapsed unresectable Stage III or IV melanoma.</li>\n <li>The trial is enrolling a total of 120 patients. The primary endpoint is the overall response rate (ORR) of BNT111 in combination with Libtayo.</li>\n <li>Secondary endpoints include ORR in the single agent arms, duration of response, and safety.</li>\n <li>The first patient has been dosed in the EU. BioNTech retains global commercial rights to BNT111.</li>\n <li>This Phase 2 clinical trial is based on previous results from the Phase 1 Lipo-MERIT dose escalation trial that demonstrated a favorable safety profile in 89 patients with advanced melanoma.</li>\n <li>The Company also plans to start randomized Phase 2 trials with mRNA vaccine product candidates in two additional programs in 2021 (FixVac: BNT113 and iNeST: BNT122).</li>\n <li>The BNT111-01 trial is being conducted in collaboration with Regeneron.</li>\n <li>BioNTech CEO Ugur Sahin warns of possible COVID resurgence from Delta variant</li>\n</ul>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Dosing underway in BioNTech's Phase 2 trial of mrna-based BNT111 in advanced melanoma</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDosing underway in BioNTech's Phase 2 trial of mrna-based BNT111 in advanced melanoma\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-18 17:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3707553-dosing-underway-in-biontechs-phase-2-trial-of-mrna-based-bnt111-in-advanced-melanoma><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BioNTech(NASDAQ:BNTX)announcesthat the first patient has been treated in its Phase 2 cancer vaccine trial, evaluating the Company’s BNT111in combination with Libtayo (cemiplimab), being co-developed ...</p>\n\n<a href=\"https://seekingalpha.com/news/3707553-dosing-underway-in-biontechs-phase-2-trial-of-mrna-based-bnt111-in-advanced-melanoma\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE"},"source_url":"https://seekingalpha.com/news/3707553-dosing-underway-in-biontechs-phase-2-trial-of-mrna-based-bnt111-in-advanced-melanoma","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1166489816","content_text":"BioNTech(NASDAQ:BNTX)announcesthat the first patient has been treated in its Phase 2 cancer vaccine trial, evaluating the Company’s BNT111in combination with Libtayo (cemiplimab), being co-developed by Regeneron(NASDAQ:REGN)and Sanofi(NASDAQ:SNY)in patients with anti-PD1-refractory/relapsed unresectable Stage III or IV melanoma.\nThe trial is enrolling a total of 120 patients. The primary endpoint is the overall response rate (ORR) of BNT111 in combination with Libtayo.\nSecondary endpoints include ORR in the single agent arms, duration of response, and safety.\nThe first patient has been dosed in the EU. BioNTech retains global commercial rights to BNT111.\nThis Phase 2 clinical trial is based on previous results from the Phase 1 Lipo-MERIT dose escalation trial that demonstrated a favorable safety profile in 89 patients with advanced melanoma.\nThe Company also plans to start randomized Phase 2 trials with mRNA vaccine product candidates in two additional programs in 2021 (FixVac: BNT113 and iNeST: BNT122).\nThe BNT111-01 trial is being conducted in collaboration with Regeneron.\nBioNTech CEO Ugur Sahin warns of possible COVID resurgence from Delta variant","news_type":1},"isVote":1,"tweetType":1,"viewCount":69,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":161206147,"gmtCreate":1623926723989,"gmtModify":1631892621112,"author":{"id":"3570873824164040","authorId":"3570873824164040","name":"MaxTay","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570873824164040","authorIdStr":"3570873824164040"},"themes":[],"htmlText":"Quest","listText":"Quest","text":"Quest","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/161206147","repostId":"2144743318","repostType":4,"isVote":1,"tweetType":1,"viewCount":122,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":161201549,"gmtCreate":1623926615081,"gmtModify":1631892621116,"author":{"id":"3570873824164040","authorId":"3570873824164040","name":"MaxTay","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570873824164040","authorIdStr":"3570873824164040"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/161201549","repostId":"2144271757","repostType":4,"isVote":1,"tweetType":1,"viewCount":151,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":169412401,"gmtCreate":1623847129003,"gmtModify":1631892621119,"author":{"id":"3570873824164040","authorId":"3570873824164040","name":"MaxTay","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570873824164040","authorIdStr":"3570873824164040"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/169412401","repostId":"2143799148","repostType":4,"isVote":1,"tweetType":1,"viewCount":117,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":169419727,"gmtCreate":1623846957669,"gmtModify":1631892621121,"author":{"id":"3570873824164040","authorId":"3570873824164040","name":"MaxTay","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570873824164040","authorIdStr":"3570873824164040"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/169419727","repostId":"2143799148","repostType":4,"isVote":1,"tweetType":1,"viewCount":132,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187491639,"gmtCreate":1623761128821,"gmtModify":1631892621128,"author":{"id":"3570873824164040","authorId":"3570873824164040","name":"MaxTay","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570873824164040","authorIdStr":"3570873824164040"},"themes":[],"htmlText":"Tiger broker 1st post","listText":"Tiger broker 1st post","text":"Tiger broker 1st post","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/187491639","isVote":1,"tweetType":1,"viewCount":102,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":128587199,"gmtCreate":1624523938511,"gmtModify":1631891440595,"author":{"id":"3570873824164040","authorId":"3570873824164040","name":"MaxTay","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570873824164040","authorIdStr":"3570873824164040"},"themes":[],"htmlText":"Like and comment, thanks guys&nbsp;","listText":"Like and comment, thanks guys&nbsp;","text":"Like and comment, thanks guys","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/128587199","repostId":"1186718506","repostType":4,"repost":{"id":"1186718506","kind":"news","pubTimestamp":1624523657,"share":"https://www.laohu8.com/m/news/1186718506?lang=&edition=full","pubTime":"2021-06-24 16:34","market":"us","language":"en","title":"Vipshop Holdings: A Solid Valuation Play","url":"https://stock-news.laohu8.com/highlight/detail?id=1186718506","media":"seekingalpha","summary":"Summary\n\nSolid valuation play with strong fundamentals.\nOwner-operated business with a meaningful ow","content":"<p><b>Summary</b></p>\n<ul>\n <li>Solid valuation play with strong fundamentals.</li>\n <li>Owner-operated business with a meaningful ownership stakes in the company.</li>\n <li>Cooperation with JD.com and Tencent provides opportunity for future growth.</li>\n</ul>\n<p><b>Investment Thesis</b></p>\n<p><b>Vipshop Holdings Ltd. (VIPS)</b>&nbsp;is a Chinese online retailer with a focus on sale of discounted branded products in limited quantities for a short period of time, also known in the retail industry as a flash sales business model. The stock price went through a roller-coaster ride when in the first two months of this year generated a return of 60% just to give it all back and ended this month with a YTD loss of nearly 40%. In the past few months, the stock was affected by the investigation of Chinese regulators for unfair retail practices, which continued with a selloff due to the block trade tied to the collapse of hedge fund Archegos. If this was not enough, then the current discussion about the regulation of Chinese e-commerce companies is putting additional pressure on the stock performance. In the following paragraphs, I want to show that behind the negative sentiment hides a company with growing revenues and solid fundaments which are unfairly discounted at the current price.</p>\n<p><img src=\"https://static.tigerbbs.com/34c55d9a6241719942a6f034ead1e063\" tg-width=\"640\" tg-height=\"379\"></p>\n<p><i>Source: Bloomberg</i></p>\n<p><b>Company overview</b></p>\n<p>Before jumping straight into operational characteristics, it is always good to look at the ownership structure of the company. The company has two classes of shares. Class B shares are 100% owned by its CEO and founder Eric Ya Shen, who owns 12% of total shares. Another co-founder Arthur Xiaobo Hong owns 6.9% of total shares. These two founders together own 19% of the company stock. It is always good to see that both founders have \"skin in the game\" and their ownership stakes constitute majority of their net worth. Other major investors are Tencent(OTCPK:TCEHY)and JD.com(NASDAQ:JD)which altogether hold a 17% stake in the company, which I consider to be a proof that Vipshop is a solid company, not just some e-commerce scam.</p>\n<p>This alliance with Tencent and JD.com serves to protect Vipshop's business model from major competitors, especially Alibaba(NYSE:BABA)and Pinduoduo(NASDAQ:PDD), due to lowering acquisition costs of new customers and at the same time re-directing these customers to the Vipshop platform. At the end of Q1 2021, Vipshop had 46 million customers, GMV of USD 7.1 billion and cooperated with approximately 21,000 brands. That is quite impressive compared to what this business is currently worth.</p>\n<p><b>Valuation</b></p>\n<p>With Chinese tech companies, it is generally true that they are either loved or hated. You can buy them either with a huge premium or a big discount compared to their intrinsic value. In case of Vipshop, I would argue that is unfairly discounted, which makes it an attractive buying opportunity at current prices.</p>\n<p>There are several ways how an investor can look at the valuation of the company. In this analysis, I look at the valuation from several perspectives. More specifically, I look at the multiples of the company versus its historical multiples, the multiples of the competition and finally multiples of the market itself. I understand that some might argue that a proper valuation of the company requires a DCF analysis, but in this case, I think that relative valuation is sufficient to prove the point.</p>\n<p><img src=\"https://static.tigerbbs.com/b9c6aa80618d53dfe075349bcfb66f14\" tg-width=\"613\" tg-height=\"103\" referrerpolicy=\"no-referrer\"></p>\n<p>At current levels, VIPS is trading approximately 30% below is 2-year average. Comparing VIPS to index SP500, the difference is even more striking. The same pattern is visible if you compare VIPS to its closest competitors: Alibaba, Pinduoduo and JD.com</p>\n<p><img src=\"https://static.tigerbbs.com/8eab4b8077e4df714728dfc2ee7787c7\" tg-width=\"512\" tg-height=\"104\"></p>\n<p>From a fundamental perspective, VIPS looks like a solid investment. It is net cash positive (USD 2.3 billion in 1Q21) and generates over USD 1.1 billion in FCFF with FCFF yield over 11%. Based on the management comments, it expects to grow revenues from 20% to 25% in Q2 and c. 30% in FY21. Additionally, it expects to repurchase USD 500 mil. worth of shares in next two years.</p>\n<p><b>Summary</b></p>\n<p>After a string of negative events in the past 4 months, VIPS underwent a path from being a darling of the market to become a total underdog. Even though, the stock collapsed more than 60% from the top, the underlying business is still intact and fundamentally strong. The business itself is net cash positive, generating positive FCFF. All in all, VIPS is a valuation play which offers 30% to 40% discount at the current price. Can VIPS trade even lower? Yes, it definitely can. However, patient investors who are willing to slowly build their position and who can wait for the valuation gap to close can be rewarded with above-average return in the not-so-distant future.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vipshop Holdings: A Solid Valuation Play</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVipshop Holdings: A Solid Valuation Play\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-24 16:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4436316-vipshop-holdings-solid-valuation-play><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Summary\n\nSolid valuation play with strong fundamentals.\nOwner-operated business with a meaningful ownership stakes in the company.\nCooperation with JD.com and Tencent provides opportunity for future ...</p>\n\n<a href=\"https://seekingalpha.com/article/4436316-vipshop-holdings-solid-valuation-play\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VIPS":"唯品会"},"source_url":"https://seekingalpha.com/article/4436316-vipshop-holdings-solid-valuation-play","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1186718506","content_text":"Summary\n\nSolid valuation play with strong fundamentals.\nOwner-operated business with a meaningful ownership stakes in the company.\nCooperation with JD.com and Tencent provides opportunity for future growth.\n\nInvestment Thesis\nVipshop Holdings Ltd. (VIPS) is a Chinese online retailer with a focus on sale of discounted branded products in limited quantities for a short period of time, also known in the retail industry as a flash sales business model. The stock price went through a roller-coaster ride when in the first two months of this year generated a return of 60% just to give it all back and ended this month with a YTD loss of nearly 40%. In the past few months, the stock was affected by the investigation of Chinese regulators for unfair retail practices, which continued with a selloff due to the block trade tied to the collapse of hedge fund Archegos. If this was not enough, then the current discussion about the regulation of Chinese e-commerce companies is putting additional pressure on the stock performance. In the following paragraphs, I want to show that behind the negative sentiment hides a company with growing revenues and solid fundaments which are unfairly discounted at the current price.\n\nSource: Bloomberg\nCompany overview\nBefore jumping straight into operational characteristics, it is always good to look at the ownership structure of the company. The company has two classes of shares. Class B shares are 100% owned by its CEO and founder Eric Ya Shen, who owns 12% of total shares. Another co-founder Arthur Xiaobo Hong owns 6.9% of total shares. These two founders together own 19% of the company stock. It is always good to see that both founders have \"skin in the game\" and their ownership stakes constitute majority of their net worth. Other major investors are Tencent(OTCPK:TCEHY)and JD.com(NASDAQ:JD)which altogether hold a 17% stake in the company, which I consider to be a proof that Vipshop is a solid company, not just some e-commerce scam.\nThis alliance with Tencent and JD.com serves to protect Vipshop's business model from major competitors, especially Alibaba(NYSE:BABA)and Pinduoduo(NASDAQ:PDD), due to lowering acquisition costs of new customers and at the same time re-directing these customers to the Vipshop platform. At the end of Q1 2021, Vipshop had 46 million customers, GMV of USD 7.1 billion and cooperated with approximately 21,000 brands. That is quite impressive compared to what this business is currently worth.\nValuation\nWith Chinese tech companies, it is generally true that they are either loved or hated. You can buy them either with a huge premium or a big discount compared to their intrinsic value. In case of Vipshop, I would argue that is unfairly discounted, which makes it an attractive buying opportunity at current prices.\nThere are several ways how an investor can look at the valuation of the company. In this analysis, I look at the valuation from several perspectives. More specifically, I look at the multiples of the company versus its historical multiples, the multiples of the competition and finally multiples of the market itself. I understand that some might argue that a proper valuation of the company requires a DCF analysis, but in this case, I think that relative valuation is sufficient to prove the point.\n\nAt current levels, VIPS is trading approximately 30% below is 2-year average. Comparing VIPS to index SP500, the difference is even more striking. The same pattern is visible if you compare VIPS to its closest competitors: Alibaba, Pinduoduo and JD.com\n\nFrom a fundamental perspective, VIPS looks like a solid investment. It is net cash positive (USD 2.3 billion in 1Q21) and generates over USD 1.1 billion in FCFF with FCFF yield over 11%. Based on the management comments, it expects to grow revenues from 20% to 25% in Q2 and c. 30% in FY21. Additionally, it expects to repurchase USD 500 mil. worth of shares in next two years.\nSummary\nAfter a string of negative events in the past 4 months, VIPS underwent a path from being a darling of the market to become a total underdog. Even though, the stock collapsed more than 60% from the top, the underlying business is still intact and fundamentally strong. The business itself is net cash positive, generating positive FCFF. All in all, VIPS is a valuation play which offers 30% to 40% discount at the current price. Can VIPS trade even lower? Yes, it definitely can. However, patient investors who are willing to slowly build their position and who can wait for the valuation gap to close can be rewarded with above-average return in the not-so-distant future.","news_type":1},"isVote":1,"tweetType":1,"viewCount":156,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":165064669,"gmtCreate":1624082010451,"gmtModify":1631891440632,"author":{"id":"3570873824164040","authorId":"3570873824164040","name":"MaxTay","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570873824164040","authorIdStr":"3570873824164040"},"themes":[],"htmlText":"Come and like","listText":"Come and like","text":"Come and like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/165064669","repostId":"1141597711","repostType":4,"isVote":1,"tweetType":1,"viewCount":368,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":169412401,"gmtCreate":1623847129003,"gmtModify":1631892621119,"author":{"id":"3570873824164040","authorId":"3570873824164040","name":"MaxTay","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570873824164040","authorIdStr":"3570873824164040"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/169412401","repostId":"2143799148","repostType":4,"isVote":1,"tweetType":1,"viewCount":117,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":161201549,"gmtCreate":1623926615081,"gmtModify":1631892621116,"author":{"id":"3570873824164040","authorId":"3570873824164040","name":"MaxTay","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570873824164040","authorIdStr":"3570873824164040"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/161201549","repostId":"2144271757","repostType":4,"isVote":1,"tweetType":1,"viewCount":151,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":124752110,"gmtCreate":1624796439130,"gmtModify":1631891440557,"author":{"id":"3570873824164040","authorId":"3570873824164040","name":"MaxTay","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570873824164040","authorIdStr":"3570873824164040"},"themes":[],"htmlText":"Help me get a T","listText":"Help me get a T","text":"Help me get a T","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/124752110","repostId":"2146090006","repostType":4,"repost":{"id":"2146090006","kind":"highlight","pubTimestamp":1624755315,"share":"https://www.laohu8.com/m/news/2146090006?lang=&edition=full","pubTime":"2021-06-27 08:55","market":"us","language":"en","title":"5 Buffett Stocks to Buy Hand Over Fist for the Second Half of 2021","url":"https://stock-news.laohu8.com/highlight/detail?id=2146090006","media":"Motley Fool","summary":"These growth and value stocks are begging to be bought by investors.","content":"<p>When Warren Buffett buys or sells a stock, Wall Street and retail investors tend to pay very close attention. That's because the Oracle of Omaha's track record is virtually unsurpassed. Since taking the reins of <b>Berkshire Hathaway</b> (NYSE:BRK.A)(NYSE:BRK.B) in the mid-1960s, Buffett's company has averaged an annual return of 20%. This works out to an aggregate gain of greater than 2,800,000% for its Class A shares.</p>\n<p>Although Buffett isn't perfect, he and his investing team have a knack for identifying attractively valued businesses that have clear competitive advantages. As we prepare to move into the second half of 2021, the following five Buffett stocks stand out as those that should be bought hand over fist.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1077c8372814d2b8150e933b4c608005\" tg-width=\"700\" tg-height=\"466\"><span>Berkshire Hathaway CEO Warren Buffett. Image source: The Motley Fool.</span></p>\n<h2>Amazon</h2>\n<p>Even though Buffett's investing lieutenants, Todd Combs and Ted Weschler, are the architects behind Berkshire Hathaway's stake in <b>Amazon</b> (NASDAQ:AMZN), it's arguably the Buffett stock that should be bought most aggressively ahead of the second half of the year.</p>\n<p>As most folks probably know, Amazon is an e-commerce juggernaut. Based on an April report from eMarketer, the company effectively controls $0.40 of every $1 spent online in the United States. It's also pivoted its online retail popularity into signing up more than 200 million people to its Prime program worldwide. The fees Amazon collects from Prime help it to undercut its competition on price. And it certainly doesn't hurt that Prime members tend to spend many multiples more than non-Prime shoppers during the course of the year.</p>\n<p>But it's the company's cloud infrastructure service, Amazon Web Services (AWS), that has truly budded into a star. Since the operating margins associated with cloud infrastructure are considerably higher than what Amazon nets from retail and advertising, AWS' growth is leading to a surge in operating cash flow. If investors were to continue to pay the midpoint of Amazon's operating cash flow multiple over the past decade, it could hit $10,000 a share by 2025.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b18b49b2b35da2fc49e0a83b883d1c22\" tg-width=\"700\" tg-height=\"466\"><span>Image source: Getty Images.</span></p>\n<h2>Bristol Myers Squibb</h2>\n<p>Pharmaceutical stocks are money machines, and none looks to be more attractive on a valuation basis than <b>Bristol Myers Squibb</b> (NYSE:BMY).</p>\n<p>One reason to be excited about this drug developer is its organic growth potential. Eliquis, which was co-developed with <b>Pfizer</b>, has blossomed into the world's leading oral anticoagulant, with sales expected to surpass $10 billion in 2021. Meanwhile, dozens of additional clinical trials are underway for cancer immunotherapy Opdivo, which generated $7 billion in sales last year. This offers plenty of opportunity to expand Opdivo's label and pump up its pricing power.</p>\n<p>Another reason Bristol Myers Squibb is such an intriguing stock is its November 2019 acquisition of cancer and immunology company Celgene. Buying Celgene brought the blockbuster multiple-myeloma drug Revlimid into the fold. Revlimid has sustainably grown its annual sales by a double-digit percentage for more than a decade, with label expansion, longer duration of use, and pricing power all playing a role. This key treatment, which topped $12 billion in sales last year, is protected from a full onslaught of generic competition until early 2026. That means Bristol Myers will be rolling in the dough for another five years, at minimum.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1b152e369d7c967dcbc926192ee888c1\" tg-width=\"700\" tg-height=\"531\"><span>Image source: Getty Images.</span></p>\n<h2>Mastercard</h2>\n<p>Everyone seems to be looking for the smartest recovery play from the pandemic. Payment processor <b>Mastercard</b> (NYSE:MA) might well be the safest way to take advantage of a steady uptick in consumer and enterprise spending.</p>\n<p>Mastercard isn't a cheap stock by any means -- at 36 times Wall Street's forward-year earnings consensus -- but it benefits from a simple numbers game. While economic contractions and recessions are inevitable, these periods of turbulence tend to be short-lived. By comparison, economic expansions often last many years. Buying into Mastercard allows investors to take full advantage of these long periods of economic expansion and robust spending. Plus, it doesn't hurt that Mastercard has the second-highest share of credit-card network purchase volume in the U.S., the leading market for consumption.</p>\n<p>Investors can also sleep easy with the understanding that Mastercard strictly sticks to payment facilitation. Even though some of its peers also lend, and are therefore able to generate interest income and fees during bull markets, Mastercard has avoided becoming a lender. It's something you'll truly appreciate when a recession strikes. Whereas most financial stocks will be forced to set aside capital to cover credit or loan delinquencies, Mastercard won't have to. This is a big reason it bounces back from recessions quicker than most financial stocks.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/e4e1a1fe028efa4c966b66ef2cd466f5\" tg-width=\"700\" tg-height=\"466\"><span>Image source: Getty Images.</span></p>\n<h2>Teva Pharmaceutical Industries</h2>\n<p>If you have an appetite for turnaround plays, brand-name and generic-drug developer <b>Teva Pharmaceutical Industries</b> (NYSE:TEVA) is the stock to buy hand over fist for the second half of 2021. Like Amazon, it's a stock that was added to Berkshire Hathaway's portfolio by either Combs or Weschler and not Buffett.</p>\n<p>While there's no denying that Teva has its fair share of hurdles to overcome, the company's turnaround-focused CEO, Kare Schultz, has been a blessing. Since taking the helm less than four years ago, Schultz has helped shave off more than $10 billion in net debt, and he's overseen the reduction of roughly $3 billion in annual operating expenses. There's more work to do to improve Teva's balance sheet, but the company is very clearly on much firmer ground than it was back in 2016-2017.</p>\n<p>Schultz also has the potential to play peacemaker for a number of outstanding lawsuits targeting Teva's role in the opioid crisis. If this litigation can be resolved with minimal cash outlay, Teva's valuation could soar. At just 4 times the company's projected earnings in 2021, Teva is about as cheap as a healthcare stock can get.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/44a30c4dfd6886a29e22d3c6558c3e56\" tg-width=\"700\" tg-height=\"466\"><span>Image source: Getty Images.</span></p>\n<h2>Bank of America</h2>\n<p>Lastly, bank stock <b>Bank of America</b> (NYSE:BAC) has the look of a company that can be confidently bought hand over fist for the second half of 2021.</p>\n<p>For much of the past decade, the Federal Reserve has kept interest rates at or near historic lows. That's meant less in the way of interest income for banks. But the latest update from the nation's central bank suggests that interest rates could begin creeping up in 2023, a year earlier than previously forecast. Bank of America is the most interest-sensitive money-center bank. According to its first-quarter investor presentation, BofA would generate $8.3 billion in net interest income on a 100-basis-point shift in the interest rate yield curve. Translation: Bank of America's profits should rocket higher beginning in 2023-2024.</p>\n<p>At the same time, BofA has done an outstanding job of controlling its costs and improving its operating efficiency. Investments in digitization have resulted in higher mobile app and digital banking use, which is allowing the company to consolidate some of its branches. Even with its shares at a 13-year high, Bank of America has plenty left in the tank.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Buffett Stocks to Buy Hand Over Fist for the Second Half of 2021</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Buffett Stocks to Buy Hand Over Fist for the Second Half of 2021\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-27 08:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/26/buffett-stocks-buy-hand-over-fist-second-half-2021/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>When Warren Buffett buys or sells a stock, Wall Street and retail investors tend to pay very close attention. That's because the Oracle of Omaha's track record is virtually unsurpassed. Since taking ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/26/buffett-stocks-buy-hand-over-fist-second-half-2021/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BAC":"美国银行","MA":"万事达","BRK.A":"伯克希尔","TEVA":"梯瓦制药","AMZN":"亚马逊","BMY":"施贵宝","BRK.B":"伯克希尔B"},"source_url":"https://www.fool.com/investing/2021/06/26/buffett-stocks-buy-hand-over-fist-second-half-2021/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2146090006","content_text":"When Warren Buffett buys or sells a stock, Wall Street and retail investors tend to pay very close attention. That's because the Oracle of Omaha's track record is virtually unsurpassed. Since taking the reins of Berkshire Hathaway (NYSE:BRK.A)(NYSE:BRK.B) in the mid-1960s, Buffett's company has averaged an annual return of 20%. This works out to an aggregate gain of greater than 2,800,000% for its Class A shares.\nAlthough Buffett isn't perfect, he and his investing team have a knack for identifying attractively valued businesses that have clear competitive advantages. As we prepare to move into the second half of 2021, the following five Buffett stocks stand out as those that should be bought hand over fist.\nBerkshire Hathaway CEO Warren Buffett. Image source: The Motley Fool.\nAmazon\nEven though Buffett's investing lieutenants, Todd Combs and Ted Weschler, are the architects behind Berkshire Hathaway's stake in Amazon (NASDAQ:AMZN), it's arguably the Buffett stock that should be bought most aggressively ahead of the second half of the year.\nAs most folks probably know, Amazon is an e-commerce juggernaut. Based on an April report from eMarketer, the company effectively controls $0.40 of every $1 spent online in the United States. It's also pivoted its online retail popularity into signing up more than 200 million people to its Prime program worldwide. The fees Amazon collects from Prime help it to undercut its competition on price. And it certainly doesn't hurt that Prime members tend to spend many multiples more than non-Prime shoppers during the course of the year.\nBut it's the company's cloud infrastructure service, Amazon Web Services (AWS), that has truly budded into a star. Since the operating margins associated with cloud infrastructure are considerably higher than what Amazon nets from retail and advertising, AWS' growth is leading to a surge in operating cash flow. If investors were to continue to pay the midpoint of Amazon's operating cash flow multiple over the past decade, it could hit $10,000 a share by 2025.\nImage source: Getty Images.\nBristol Myers Squibb\nPharmaceutical stocks are money machines, and none looks to be more attractive on a valuation basis than Bristol Myers Squibb (NYSE:BMY).\nOne reason to be excited about this drug developer is its organic growth potential. Eliquis, which was co-developed with Pfizer, has blossomed into the world's leading oral anticoagulant, with sales expected to surpass $10 billion in 2021. Meanwhile, dozens of additional clinical trials are underway for cancer immunotherapy Opdivo, which generated $7 billion in sales last year. This offers plenty of opportunity to expand Opdivo's label and pump up its pricing power.\nAnother reason Bristol Myers Squibb is such an intriguing stock is its November 2019 acquisition of cancer and immunology company Celgene. Buying Celgene brought the blockbuster multiple-myeloma drug Revlimid into the fold. Revlimid has sustainably grown its annual sales by a double-digit percentage for more than a decade, with label expansion, longer duration of use, and pricing power all playing a role. This key treatment, which topped $12 billion in sales last year, is protected from a full onslaught of generic competition until early 2026. That means Bristol Myers will be rolling in the dough for another five years, at minimum.\nImage source: Getty Images.\nMastercard\nEveryone seems to be looking for the smartest recovery play from the pandemic. Payment processor Mastercard (NYSE:MA) might well be the safest way to take advantage of a steady uptick in consumer and enterprise spending.\nMastercard isn't a cheap stock by any means -- at 36 times Wall Street's forward-year earnings consensus -- but it benefits from a simple numbers game. While economic contractions and recessions are inevitable, these periods of turbulence tend to be short-lived. By comparison, economic expansions often last many years. Buying into Mastercard allows investors to take full advantage of these long periods of economic expansion and robust spending. Plus, it doesn't hurt that Mastercard has the second-highest share of credit-card network purchase volume in the U.S., the leading market for consumption.\nInvestors can also sleep easy with the understanding that Mastercard strictly sticks to payment facilitation. Even though some of its peers also lend, and are therefore able to generate interest income and fees during bull markets, Mastercard has avoided becoming a lender. It's something you'll truly appreciate when a recession strikes. Whereas most financial stocks will be forced to set aside capital to cover credit or loan delinquencies, Mastercard won't have to. This is a big reason it bounces back from recessions quicker than most financial stocks.\nImage source: Getty Images.\nTeva Pharmaceutical Industries\nIf you have an appetite for turnaround plays, brand-name and generic-drug developer Teva Pharmaceutical Industries (NYSE:TEVA) is the stock to buy hand over fist for the second half of 2021. Like Amazon, it's a stock that was added to Berkshire Hathaway's portfolio by either Combs or Weschler and not Buffett.\nWhile there's no denying that Teva has its fair share of hurdles to overcome, the company's turnaround-focused CEO, Kare Schultz, has been a blessing. Since taking the helm less than four years ago, Schultz has helped shave off more than $10 billion in net debt, and he's overseen the reduction of roughly $3 billion in annual operating expenses. There's more work to do to improve Teva's balance sheet, but the company is very clearly on much firmer ground than it was back in 2016-2017.\nSchultz also has the potential to play peacemaker for a number of outstanding lawsuits targeting Teva's role in the opioid crisis. If this litigation can be resolved with minimal cash outlay, Teva's valuation could soar. At just 4 times the company's projected earnings in 2021, Teva is about as cheap as a healthcare stock can get.\nImage source: Getty Images.\nBank of America\nLastly, bank stock Bank of America (NYSE:BAC) has the look of a company that can be confidently bought hand over fist for the second half of 2021.\nFor much of the past decade, the Federal Reserve has kept interest rates at or near historic lows. That's meant less in the way of interest income for banks. But the latest update from the nation's central bank suggests that interest rates could begin creeping up in 2023, a year earlier than previously forecast. Bank of America is the most interest-sensitive money-center bank. According to its first-quarter investor presentation, BofA would generate $8.3 billion in net interest income on a 100-basis-point shift in the interest rate yield curve. Translation: Bank of America's profits should rocket higher beginning in 2023-2024.\nAt the same time, BofA has done an outstanding job of controlling its costs and improving its operating efficiency. Investments in digitization have resulted in higher mobile app and digital banking use, which is allowing the company to consolidate some of its branches. Even with its shares at a 13-year high, Bank of America has plenty left in the tank.","news_type":1},"isVote":1,"tweetType":1,"viewCount":249,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":129377952,"gmtCreate":1624362593076,"gmtModify":1631891440621,"author":{"id":"3570873824164040","authorId":"3570873824164040","name":"MaxTay","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570873824164040","authorIdStr":"3570873824164040"},"themes":[],"htmlText":"Thanks for commenting","listText":"Thanks for commenting","text":"Thanks for commenting","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/129377952","repostId":"2145056554","repostType":4,"isVote":1,"tweetType":1,"viewCount":173,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":161206147,"gmtCreate":1623926723989,"gmtModify":1631892621112,"author":{"id":"3570873824164040","authorId":"3570873824164040","name":"MaxTay","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570873824164040","authorIdStr":"3570873824164040"},"themes":[],"htmlText":"Quest","listText":"Quest","text":"Quest","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/161206147","repostId":"2144743318","repostType":4,"repost":{"id":"2144743318","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"T-Reuters","id":"1086160438","head_image":"https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5"},"pubTimestamp":1623923313,"share":"https://www.laohu8.com/m/news/2144743318?lang=&edition=full","pubTime":"2021-06-17 17:48","market":"hk","language":"en","title":"Ko Chun Shun Johnson's Long Position In China Biotech Services Rises To 9.90% - HKEX Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2144743318","media":"T-Reuters","summary":"Hong Kong stock exchange filing:Ko Chun Shun Johnson'S Long Position In China Biotech Services <<<80","content":"<p>Hong Kong stock exchange filing:Ko Chun Shun Johnson'S Long Position In China Biotech Services &lt;&lt;&lt;8037.Hk&gt;&gt;&gt; Increased To 9.90% On June 11 From 5.74% - Hkex Filing.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ko Chun Shun Johnson's Long Position In China Biotech Services Rises To 9.90% - HKEX Filing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKo Chun Shun Johnson's Long Position In China Biotech Services Rises To 9.90% - HKEX Filing\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086160438\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">T-Reuters </p>\n<p class=\"h-time\">2021-06-17 17:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hong Kong stock exchange filing:Ko Chun Shun Johnson'S Long Position In China Biotech Services &lt;&lt;&lt;8037.Hk&gt;&gt;&gt; Increased To 9.90% On June 11 From 5.74% - Hkex Filing.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"08037":"中国生物科技服务"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2144743318","content_text":"Hong Kong stock exchange filing:Ko Chun Shun Johnson'S Long Position In China Biotech Services <<<8037.Hk>>> Increased To 9.90% On June 11 From 5.74% - Hkex Filing.","news_type":1},"isVote":1,"tweetType":1,"viewCount":122,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":121027965,"gmtCreate":1624445769157,"gmtModify":1631891440608,"author":{"id":"3570873824164040","authorId":"3570873824164040","name":"MaxTay","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570873824164040","authorIdStr":"3570873824164040"},"themes":[],"htmlText":"Comment everyday just for a T","listText":"Comment everyday just for a T","text":"Comment everyday just for a T","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/121027965","repostId":"1127447179","repostType":4,"isVote":1,"tweetType":1,"viewCount":162,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187491639,"gmtCreate":1623761128821,"gmtModify":1631892621128,"author":{"id":"3570873824164040","authorId":"3570873824164040","name":"MaxTay","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570873824164040","authorIdStr":"3570873824164040"},"themes":[],"htmlText":"Tiger broker 1st post","listText":"Tiger broker 1st post","text":"Tiger broker 1st post","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/187491639","isVote":1,"tweetType":1,"viewCount":102,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":122695762,"gmtCreate":1624615189056,"gmtModify":1631891440582,"author":{"id":"3570873824164040","authorId":"3570873824164040","name":"MaxTay","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570873824164040","authorIdStr":"3570873824164040"},"themes":[],"htmlText":"I post to get a 'T'","listText":"I post to get a 'T'","text":"I post to get a 'T'","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/122695762","repostId":"2146023165","repostType":4,"repost":{"id":"2146023165","kind":"news","pubTimestamp":1624614720,"share":"https://www.laohu8.com/m/news/2146023165?lang=&edition=full","pubTime":"2021-06-25 17:52","market":"us","language":"en","title":"Microsoft sent a strong signal to developers that could hurt Apple and Google","url":"https://stock-news.laohu8.com/highlight/detail?id=2146023165","media":"Yahoo Finance","summary":"Microsoft  launched a broadside against rivals Apple  and Google  on Thursday, announcing that the next version of Windows, called Windows 11, will feature an app store that lets developers keep 100% of the revenue from sales of their apps.That’s a massive departure from the policies Apple and Google have in place that require app developers who use their stores to pay 30% fees on the sale of apps and in-app purchases.“Windows has always stood for sovereignty for creators and agency for consumer","content":"<p>Microsoft (MSFT) launched a broadside against rivals Apple (AAPL) and Google (GOOG, GOOGL) on Thursday, announcing that the next version of Windows, called Windows 11, will feature an app store that lets developers keep 100% of the revenue from sales of their apps.</p>\n<p>That’s a massive departure from the policies Apple and Google have in place that require app developers who use their stores to pay 30% fees on the sale of apps and in-app purchases.</p>\n<p>“Windows has always stood for sovereignty for creators and agency for consumers,” Microsoft CEO Satya Nadella said. “A platform can only serve society if its rules allow for this foundational innovation and category creation. It’s why we’re introducing new store commerce models and policies.”</p>\n<p>The move is certain to rankle executives at both Apple and Google, which are facing antitrust investigations into their app store practices.</p>\n<p>Apple is awaiting a ruling in an antitrust case brought by Epic Games, in which the “Fortnite” developer accused the iPhone maker of abusing its market power over the App Store by forcing developers to use its own payment system and fork over the associated fees.</p>\n<p>Google, meanwhile, faces a similar lawsuit from Epic and is expected to get slapped with a lawsuit from a collection of state attorneys general for its app store policies.</p>\n<h3><b>Microsoft has been criticizing Apple’s policies</b></h3>\n<p>This isn’t the first time Microsoft has called out its rivals and their app stores. The company has criticized Apple’s policies in the past, specifically Apple’s policy of taking a share of revenue from Microsoft apps purchased through the Apple App Store.</p>\n<p>More recently, Microsoft sparred with Apple over its desire to get its xCloud cloud gaming platform onto the iPhone via a native app. Apple has pushed back, hampering Microsoft’s cloud gaming ambitions and forcing it to make users rely on a browser-style app.</p>\n<p>That led Microsoft to meet and lodge a complaint with members of the House Antitrust Subcommittee during the body’s investigation into Apple, Google, Amazon, and <a href=\"https://laohu8.com/S/FB\">Facebook</a>.</p>\n<p><img src=\"https://static.tigerbbs.com/d92ddac610658f60945c72fc4da23210\" tg-width=\"1024\" tg-height=\"640\" referrerpolicy=\"no-referrer\">Microsoft has debuted the latest version of its Windows operating system: Windows 11. (Image: Microsoft)Microsoft</p>\n<p>Microsoft also took aim at Apple in the iPhone maker’s battle with “Fortnite” developer Epic Games. In that instance, Microsoft filed a statement of support for Epic in its fight to prevent Apple withholding iOS support for Epic’s Unreal Engine.</p>\n<p>Epic initially sued Apple and Google after the two companies removed “Fornite” from their respective app stores. Apple and Google argue that Epic implemented an update that added a separate payment system allowing consumers to circumvent Apple or Google’s payment services. That effectively cut out Apple and Google’s 30% app store fees.</p>\n<p>Epic’s fight with Apple wrapped up earlier this month and a ruling is expected before the end of the summer.</p>\n<h3><b>Microsoft could win over developers</b></h3>\n<p>With its decision to allow developers to use their own payment systems, Microsoft is sending a signal to the global developer community that it is willing to play by their rules. That could help the company as it seeks to build out its app store and drive more business for Windows.</p>\n<p>While Microsoft was caught flat-footed in the smartphone wars, its moves with the Windows 11 Microsoft Store could give it the kind of boost from developers that it needs to begin taking market share from Apple and Google in the fight for app store supremacy. It’s now up to Apple and Google to respond.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Microsoft sent a strong signal to developers that could hurt Apple and Google</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMicrosoft sent a strong signal to developers that could hurt Apple and Google\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-25 17:52 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/microsoft-app-store-revenue-google-apple-200213646.html><strong>Yahoo Finance</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Microsoft (MSFT) launched a broadside against rivals Apple (AAPL) and Google (GOOG, GOOGL) on Thursday, announcing that the next version of Windows, called Windows 11, will feature an app store that ...</p>\n\n<a href=\"https://finance.yahoo.com/news/microsoft-app-store-revenue-google-apple-200213646.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MSFT":"微软","09086":"华夏纳指-U","GOOG":"谷歌","QNETCN":"纳斯达克中美互联网老虎指数","GOOGL":"谷歌A","AAPL":"苹果","03086":"华夏纳指"},"source_url":"https://finance.yahoo.com/news/microsoft-app-store-revenue-google-apple-200213646.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2146023165","content_text":"Microsoft (MSFT) launched a broadside against rivals Apple (AAPL) and Google (GOOG, GOOGL) on Thursday, announcing that the next version of Windows, called Windows 11, will feature an app store that lets developers keep 100% of the revenue from sales of their apps.\nThat’s a massive departure from the policies Apple and Google have in place that require app developers who use their stores to pay 30% fees on the sale of apps and in-app purchases.\n“Windows has always stood for sovereignty for creators and agency for consumers,” Microsoft CEO Satya Nadella said. “A platform can only serve society if its rules allow for this foundational innovation and category creation. It’s why we’re introducing new store commerce models and policies.”\nThe move is certain to rankle executives at both Apple and Google, which are facing antitrust investigations into their app store practices.\nApple is awaiting a ruling in an antitrust case brought by Epic Games, in which the “Fortnite” developer accused the iPhone maker of abusing its market power over the App Store by forcing developers to use its own payment system and fork over the associated fees.\nGoogle, meanwhile, faces a similar lawsuit from Epic and is expected to get slapped with a lawsuit from a collection of state attorneys general for its app store policies.\nMicrosoft has been criticizing Apple’s policies\nThis isn’t the first time Microsoft has called out its rivals and their app stores. The company has criticized Apple’s policies in the past, specifically Apple’s policy of taking a share of revenue from Microsoft apps purchased through the Apple App Store.\nMore recently, Microsoft sparred with Apple over its desire to get its xCloud cloud gaming platform onto the iPhone via a native app. Apple has pushed back, hampering Microsoft’s cloud gaming ambitions and forcing it to make users rely on a browser-style app.\nThat led Microsoft to meet and lodge a complaint with members of the House Antitrust Subcommittee during the body’s investigation into Apple, Google, Amazon, and Facebook.\nMicrosoft has debuted the latest version of its Windows operating system: Windows 11. (Image: Microsoft)Microsoft\nMicrosoft also took aim at Apple in the iPhone maker’s battle with “Fortnite” developer Epic Games. In that instance, Microsoft filed a statement of support for Epic in its fight to prevent Apple withholding iOS support for Epic’s Unreal Engine.\nEpic initially sued Apple and Google after the two companies removed “Fornite” from their respective app stores. Apple and Google argue that Epic implemented an update that added a separate payment system allowing consumers to circumvent Apple or Google’s payment services. That effectively cut out Apple and Google’s 30% app store fees.\nEpic’s fight with Apple wrapped up earlier this month and a ruling is expected before the end of the summer.\nMicrosoft could win over developers\nWith its decision to allow developers to use their own payment systems, Microsoft is sending a signal to the global developer community that it is willing to play by their rules. That could help the company as it seeks to build out its app store and drive more business for Windows.\nWhile Microsoft was caught flat-footed in the smartphone wars, its moves with the Windows 11 Microsoft Store could give it the kind of boost from developers that it needs to begin taking market share from Apple and Google in the fight for app store supremacy. It’s now up to Apple and Google to respond.","news_type":1},"isVote":1,"tweetType":1,"viewCount":287,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":169419727,"gmtCreate":1623846957669,"gmtModify":1631892621121,"author":{"id":"3570873824164040","authorId":"3570873824164040","name":"MaxTay","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570873824164040","authorIdStr":"3570873824164040"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/169419727","repostId":"2143799148","repostType":4,"repost":{"id":"2143799148","kind":"news","pubTimestamp":1623845700,"share":"https://www.laohu8.com/m/news/2143799148?lang=&edition=full","pubTime":"2021-06-16 20:15","market":"us","language":"en","title":"New UiPath Report Finds Growing Diversity and Near 100% Job Satisfaction Among RPA Professionals","url":"https://stock-news.laohu8.com/highlight/detail?id=2143799148","media":"Business Wire","summary":"Automation industry gaining momentum as 82% of students who have taken RPA courses are considering e","content":"<p><i>Automation industry gaining momentum as 82% of students who have taken RPA courses are considering entering the field full-time, according to the State of the RPA Developer Report 2021</i></p>\n<p><b>NEW YORK, Jun 16, 2021</b>--(BUSINESS WIRE)--Today at <a href=\"https://laohu8.com/S/PATH\">UiPath</a> DevCon,<b> </b>leading enterprise automation software company UiPath, Inc. (NYSE: PATH) unveiled its State of the RPA Developer Report 2021 which highlights the rapid growth of robotic process automation (RPA) careers and reveals how RPA developers feel about their future and the impact of automation on society.</p>\n<p>The survey found 97% of RPA professionals are satisfied in their careers. Of these, 63% report they are \"very satisfied,\" which is up from 51% last year—signaling that RPA developers are engaged in their work despite business disruptions over the past year. Eighty-seven percent also believe RPA will have a positive impact on society.</p>\n<p>The State of the RPA Developer Report 2021 surveyed more than 1,000 RPA developers from around the world in April 2021. Other key findings include:</p>\n<ul>\n <li><b>RPA is a fast-growing and desirable field that is relatively easy to transition into. </b>The survey found that 92% of RPA professionals think the RPA industry has a high potential for growth over the next five years. Industry hiring remains hot as 77% expect their organization to hire more RPA developers in the next 12 months, up from 70% last year. While 35% of respondents said RPA is their first professional role, RPA is not only attracting new talent to the workforce. <a href=\"https://laohu8.com/S/TWOA.U\">Two</a>-thirds of RPA developers enter from other software development roles, and 21% were formerly business analysts. Half of RPA developers said it was easy to transition into their roles.</li>\n <li><b>RPA is a diverse software development field. </b>86% of RPA professionals think RPA is more diverse or at least as diverse compared to other software development fields. There are signs of improved gender and age diversity: 20% of the RPA professionals who responded are women and half of respondents are over age 30. Promisingly, in a selection of students surveyed for the first time this year, 82% are considering a job in RPA after they graduate, citing interest in the technology and their belief that it is meaningful work.</li>\n <li><b>While developers want to stay in the field, many are looking for new jobs or are open to new opportunities. </b>Eighty percent of RPA professionals are looking for new jobs or report being open to new opportunities, though most of these job seekers (75%) want to stay in the field. The top reasons they are looking to make a change include the desire to advance their career (78%), increase their salary (78%), and learn new skills (76%).</li>\n <li><b>Like many others, RPA professionals shifted how they worked this year. </b>Eighty-five percent of respondents started working from home, and most are still doing so (as of April 2021). While 90% of RPA developers want to continue working from home at least some of the time, those who are new to remote work have faced challenges, including difficulty unplugging (47%) and collaboration (46%).</li>\n</ul>\n<p>\"Automation is awakening tremendous potential for businesses to better serve customers and to become more agile and resilient, which is expanding an entire job category to people from all backgrounds and skill levels,\" said Tom Clancy, Senior Vice President, UiPath Learning. \"It’s exciting to see both more diversity and fulfilling careers in automation blossoming. We are committed to empowering all who want to acquire RPA skills to succeed in the workplace of the future through free educational resources, training programs, and community events like UiPath DevCon.\"</p>\n<p>To learn more about the survey findings and trends, register here to join the UiPath DevCon virtual session on \"The State of the RPA Developer 2021\" on June 16 from 1–1:30 pm ET. The report is also available to download here. Join the UiPath Community to sign up for free RPA courses, view our new job board, and network with peers.</p>\n<p><b>About UiPath</b></p>\n<p>UiPath has a vision to deliver the Fully Automated Enterprise™, <a href=\"https://laohu8.com/S/AONE\">one</a> where companies use automation to unlock their greatest potential. UiPath offers an end-to-end platform for automation, combining the leading Robotic Process Automation (RPA) solution with a full suite of capabilities that enable every organization to rapidly scale digital business operations.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>New UiPath Report Finds Growing Diversity and Near 100% Job Satisfaction Among RPA Professionals</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNew UiPath Report Finds Growing Diversity and Near 100% Job Satisfaction Among RPA Professionals\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-16 20:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/uipath-report-finds-growing-diversity-120000523.html><strong>Business Wire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Automation industry gaining momentum as 82% of students who have taken RPA courses are considering entering the field full-time, according to the State of the RPA Developer Report 2021\nNEW YORK, Jun ...</p>\n\n<a href=\"https://finance.yahoo.com/news/uipath-report-finds-growing-diversity-120000523.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NGD":"New Gold","PATH":"UiPath"},"source_url":"https://finance.yahoo.com/news/uipath-report-finds-growing-diversity-120000523.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2143799148","content_text":"Automation industry gaining momentum as 82% of students who have taken RPA courses are considering entering the field full-time, according to the State of the RPA Developer Report 2021\nNEW YORK, Jun 16, 2021--(BUSINESS WIRE)--Today at UiPath DevCon, leading enterprise automation software company UiPath, Inc. (NYSE: PATH) unveiled its State of the RPA Developer Report 2021 which highlights the rapid growth of robotic process automation (RPA) careers and reveals how RPA developers feel about their future and the impact of automation on society.\nThe survey found 97% of RPA professionals are satisfied in their careers. Of these, 63% report they are \"very satisfied,\" which is up from 51% last year—signaling that RPA developers are engaged in their work despite business disruptions over the past year. Eighty-seven percent also believe RPA will have a positive impact on society.\nThe State of the RPA Developer Report 2021 surveyed more than 1,000 RPA developers from around the world in April 2021. Other key findings include:\n\nRPA is a fast-growing and desirable field that is relatively easy to transition into. The survey found that 92% of RPA professionals think the RPA industry has a high potential for growth over the next five years. Industry hiring remains hot as 77% expect their organization to hire more RPA developers in the next 12 months, up from 70% last year. While 35% of respondents said RPA is their first professional role, RPA is not only attracting new talent to the workforce. Two-thirds of RPA developers enter from other software development roles, and 21% were formerly business analysts. Half of RPA developers said it was easy to transition into their roles.\nRPA is a diverse software development field. 86% of RPA professionals think RPA is more diverse or at least as diverse compared to other software development fields. There are signs of improved gender and age diversity: 20% of the RPA professionals who responded are women and half of respondents are over age 30. Promisingly, in a selection of students surveyed for the first time this year, 82% are considering a job in RPA after they graduate, citing interest in the technology and their belief that it is meaningful work.\nWhile developers want to stay in the field, many are looking for new jobs or are open to new opportunities. Eighty percent of RPA professionals are looking for new jobs or report being open to new opportunities, though most of these job seekers (75%) want to stay in the field. The top reasons they are looking to make a change include the desire to advance their career (78%), increase their salary (78%), and learn new skills (76%).\nLike many others, RPA professionals shifted how they worked this year. Eighty-five percent of respondents started working from home, and most are still doing so (as of April 2021). While 90% of RPA developers want to continue working from home at least some of the time, those who are new to remote work have faced challenges, including difficulty unplugging (47%) and collaboration (46%).\n\n\"Automation is awakening tremendous potential for businesses to better serve customers and to become more agile and resilient, which is expanding an entire job category to people from all backgrounds and skill levels,\" said Tom Clancy, Senior Vice President, UiPath Learning. \"It’s exciting to see both more diversity and fulfilling careers in automation blossoming. We are committed to empowering all who want to acquire RPA skills to succeed in the workplace of the future through free educational resources, training programs, and community events like UiPath DevCon.\"\nTo learn more about the survey findings and trends, register here to join the UiPath DevCon virtual session on \"The State of the RPA Developer 2021\" on June 16 from 1–1:30 pm ET. The report is also available to download here. Join the UiPath Community to sign up for free RPA courses, view our new job board, and network with peers.\nAbout UiPath\nUiPath has a vision to deliver the Fully Automated Enterprise™, one where companies use automation to unlock their greatest potential. UiPath offers an end-to-end platform for automation, combining the leading Robotic Process Automation (RPA) solution with a full suite of capabilities that enable every organization to rapidly scale digital business operations.","news_type":1},"isVote":1,"tweetType":1,"viewCount":132,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":124755158,"gmtCreate":1624796533174,"gmtModify":1631891440549,"author":{"id":"3570873824164040","authorId":"3570873824164040","name":"MaxTay","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570873824164040","authorIdStr":"3570873824164040"},"themes":[],"htmlText":"Ok ok ok its hard to get a T","listText":"Ok ok ok its hard to get a T","text":"Ok ok ok its hard to get a T","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/124755158","isVote":1,"tweetType":1,"viewCount":284,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":122694491,"gmtCreate":1624615270313,"gmtModify":1631891440570,"author":{"id":"3570873824164040","authorId":"3570873824164040","name":"MaxTay","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570873824164040","authorIdStr":"3570873824164040"},"themes":[],"htmlText":"Say sth to get a 'T'","listText":"Say sth to get a 'T'","text":"Say sth to get a 'T'","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/122694491","isVote":1,"tweetType":1,"viewCount":192,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":121024326,"gmtCreate":1624445739365,"gmtModify":1631884647014,"author":{"id":"3570873824164040","authorId":"3570873824164040","name":"MaxTay","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570873824164040","authorIdStr":"3570873824164040"},"themes":[],"htmlText":"Post everyday just for a T","listText":"Post everyday just for a T","text":"Post everyday just for a T","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/121024326","isVote":1,"tweetType":1,"viewCount":144,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":129105915,"gmtCreate":1624363054537,"gmtModify":1631884647043,"author":{"id":"3570873824164040","authorId":"3570873824164040","name":"MaxTay","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570873824164040","authorIdStr":"3570873824164040"},"themes":[],"htmlText":"Post sth","listText":"Post sth","text":"Post sth","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/129105915","isVote":1,"tweetType":1,"viewCount":514,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":165065767,"gmtCreate":1624081977559,"gmtModify":1631891440642,"author":{"id":"3570873824164040","authorId":"3570873824164040","name":"MaxTay","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570873824164040","authorIdStr":"3570873824164040"},"themes":[],"htmlText":"Another post","listText":"Another post","text":"Another post","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/165065767","isVote":1,"tweetType":1,"viewCount":153,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":166415932,"gmtCreate":1624022395226,"gmtModify":1631891440654,"author":{"id":"3570873824164040","authorId":"3570873824164040","name":"MaxTay","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570873824164040","authorIdStr":"3570873824164040"},"themes":[],"htmlText":"Post, post","listText":"Post, post","text":"Post, post","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/166415932","isVote":1,"tweetType":1,"viewCount":101,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":166508320,"gmtCreate":1624015329960,"gmtModify":1631892621110,"author":{"id":"3570873824164040","authorId":"3570873824164040","name":"MaxTay","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570873824164040","authorIdStr":"3570873824164040"},"themes":[],"htmlText":"Like for me","listText":"Like for me","text":"Like for me","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/166508320","repostId":"1166489816","repostType":4,"repost":{"id":"1166489816","kind":"news","pubTimestamp":1624009298,"share":"https://www.laohu8.com/m/news/1166489816?lang=&edition=full","pubTime":"2021-06-18 17:41","market":"us","language":"en","title":"Dosing underway in BioNTech's Phase 2 trial of mrna-based BNT111 in advanced melanoma","url":"https://stock-news.laohu8.com/highlight/detail?id=1166489816","media":"seekingalpha","summary":"BioNTech(NASDAQ:BNTX)announcesthat the first patient has been treated in its Phase 2 cancer vaccine ","content":"<ul>\n <li>BioNTech(NASDAQ:BNTX)announcesthat the first patient has been treated in its Phase&nbsp;2 cancer vaccine trial, evaluating the Company’s BNT111in combination with Libtayo (cemiplimab), being co-developed by Regeneron(NASDAQ:REGN)and Sanofi(NASDAQ:SNY)in patients with anti-PD1-refractory/relapsed unresectable Stage III or IV melanoma.</li>\n <li>The trial is enrolling a total of 120 patients. The primary endpoint is the overall response rate (ORR) of BNT111 in combination with Libtayo.</li>\n <li>Secondary endpoints include ORR in the single agent arms, duration of response, and safety.</li>\n <li>The first patient has been dosed in the EU. BioNTech retains global commercial rights to BNT111.</li>\n <li>This Phase 2 clinical trial is based on previous results from the Phase 1 Lipo-MERIT dose escalation trial that demonstrated a favorable safety profile in 89 patients with advanced melanoma.</li>\n <li>The Company also plans to start randomized Phase 2 trials with mRNA vaccine product candidates in two additional programs in 2021 (FixVac: BNT113 and iNeST: BNT122).</li>\n <li>The BNT111-01 trial is being conducted in collaboration with Regeneron.</li>\n <li>BioNTech CEO Ugur Sahin warns of possible COVID resurgence from Delta variant</li>\n</ul>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Dosing underway in BioNTech's Phase 2 trial of mrna-based BNT111 in advanced melanoma</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDosing underway in BioNTech's Phase 2 trial of mrna-based BNT111 in advanced melanoma\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-18 17:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3707553-dosing-underway-in-biontechs-phase-2-trial-of-mrna-based-bnt111-in-advanced-melanoma><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BioNTech(NASDAQ:BNTX)announcesthat the first patient has been treated in its Phase 2 cancer vaccine trial, evaluating the Company’s BNT111in combination with Libtayo (cemiplimab), being co-developed ...</p>\n\n<a href=\"https://seekingalpha.com/news/3707553-dosing-underway-in-biontechs-phase-2-trial-of-mrna-based-bnt111-in-advanced-melanoma\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE"},"source_url":"https://seekingalpha.com/news/3707553-dosing-underway-in-biontechs-phase-2-trial-of-mrna-based-bnt111-in-advanced-melanoma","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1166489816","content_text":"BioNTech(NASDAQ:BNTX)announcesthat the first patient has been treated in its Phase 2 cancer vaccine trial, evaluating the Company’s BNT111in combination with Libtayo (cemiplimab), being co-developed by Regeneron(NASDAQ:REGN)and Sanofi(NASDAQ:SNY)in patients with anti-PD1-refractory/relapsed unresectable Stage III or IV melanoma.\nThe trial is enrolling a total of 120 patients. The primary endpoint is the overall response rate (ORR) of BNT111 in combination with Libtayo.\nSecondary endpoints include ORR in the single agent arms, duration of response, and safety.\nThe first patient has been dosed in the EU. BioNTech retains global commercial rights to BNT111.\nThis Phase 2 clinical trial is based on previous results from the Phase 1 Lipo-MERIT dose escalation trial that demonstrated a favorable safety profile in 89 patients with advanced melanoma.\nThe Company also plans to start randomized Phase 2 trials with mRNA vaccine product candidates in two additional programs in 2021 (FixVac: BNT113 and iNeST: BNT122).\nThe BNT111-01 trial is being conducted in collaboration with Regeneron.\nBioNTech CEO Ugur Sahin warns of possible COVID resurgence from Delta variant","news_type":1},"isVote":1,"tweetType":1,"viewCount":69,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}